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Abstract 
Diabetic retinopathy (DR) is the most common microvascular complication 
of diabetes and a leading cause of blindness. Increased vascular 
permeability in the retina following blood-retinal barrier (BRB) breakdown is 
a clinically significant event and a major cause of vision loss. VEGF 
blockade, despite being the only treatment to improve visual acuity, has a 
limited effectiveness for a majority of patients. A significant proportion of 
patients develop resistance to treatment, which implies that other factors 
are also involved in the pathology of this disease. There is currently a major 
unmet clinical need for therapeutics which target the early stages of DR 
prior to the onset of overt vascular symptoms. 
 
The aim of this thesis was to investigate early diabetes-induced changes to 
the retina and their effects on the vasculature, in order to identify novel 
potential therapeutic targets. This was achieved by investigating the effects 
of high glucose and glycated albumin on the vasculature using the mouse 
metatarsal assay, an ex vivo model of angiogenesis and the effects of 
diabetes on the retina with the streptozotocin-induced diabetic mouse. 
 
Both high glucose and glycated albumin altered angiogenesis in the 
metatarsal assay. Investigation of the diabetic mouse retina revealed 
evidence of increased inflammation and oxidative stress at the cellular and 
molecular level, accompanied with evidence of vascular leakage. qPCR 
analysis revealed an increase in Angptl6 and Lrg1 expression of which had 
not been investigated in the diabetic mouse retina before. Studies with 
transgenic mouse models implied that Lrg1 is involved in the early stages of 
pathophysiology of DR and may be a suitable therapeutic target prior to the 
onset of overt vascular symptoms. 
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Introduction  
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1 Vascular endothelium and angiogenesis 
Angiogenesis is the growth and formation of new blood vessels, which is 
essential for development of complex organisms (Ribatti & Crivellato 2012). 
In addition to its essential physiological role, it also contributes to the 
pathophysiology of various disease (Carmeliet 2003). Insufficient 
angiogenesis contributes to stroke, myocardial infarction and 
neurodegeneration, whilst excessive angiogenesis supports the growth of 
solid tumours, contributes to artherosclerosis and causes retinal damage in 
age related macular degeneration (AMD) and diabetic retinopathy (DR) 
(Carmeliet 2003). 
 
In mature healthy tissue, the vascular endothelium is predominantly in a 
quiescent state. Endothelial cells form a monolayer with varying degrees of 
pericyte coverage and associations with other perivascular cells depending 
on the vascular bed (Armulik et al. 2011). The vascular endothelium has 
multiple mechanisms that act in concert to maintain vascular integrity and 
quiescence. These include; autocrine and paracrine signalling (Cleaver & 
Melton 2003), intercellular junctional complexes (Dejana 2004) and 
interactions with the extracellular matrix (ECM) mediated by integrin 
signalling (Jain 2003). One unifying concept to both pathological vascular 
dysfunction and developmental angiogenesis is that multiple pro-angiogenic 
signals must converge to overcome these different regulatory mechanisms 
to induce a phenotypic switch from a quiescent to activated vessel. 
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1.1 Stimulation of angiogenesis 
Angiogenesis can be stimulated by a variety of signals induced by various 
stimuli such as hypoxia and inflammation (Pugh & Ratcliffe 2003; Kim et al. 
2013). These activate a sequence of events that permit the sprouting of 
new vessels. Vascular endothelial growth factor (VEGF) is the most well 
known inducer of angiogenesis. Regulation of VEGF transcription by hypoxia 
is regulated by hypoxia response elements (HRE) which are binding sites for 
the oxygen sensing transcription factor hypoxia inducible factor 1 α (HIF-
1α) (Pugh & Ratcliffe 2003; Vinores et al. 2006). Additionally VEGF mRNA 
stability is increased in hypoxia (Claffey et al. 1998). VEGF is also induced 
by the pro-inflammatory cytokines interleukin (IL)-1β (Ben-Av et al. 1995) 
and IL-6 (Cohen et al. 1996). 
 
There are many other factors involved in the induction of angiogenesis 
(Ferrara 2010), however, VEGF is considered to be one of the most 
important growth factors in both physiological and pathological 
angiogenesis. VEGF promotes proliferation, survival and migration of 
endothelial cells, predominantly through VEGFR2 signalling (Ferrara 2001). 
Transforming growth factor β (TGF-β) is another growth factor, which 
induces or inhibits angiogenesis in a context dependent manner. Signalling 
through transforming growth factor β receptor 2 (TGFβR2), activin receptor-
like kinase 1 (Alk1) and endoglin promotes angiogenesis through small 
mothers against decapentaplegic (Smad) 1/5/8 activation, whilst signalling 
through TGFβR2 and activin receptor-like kinase 5 (Alk5) promotes vessel 
quiescence through Smad 2/3 activation (Pardali et al. 2010). The 
regulation of the context dependent activity of TGF-β signalling in 
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endothelial cells therefore plays a key role in the regulation of angiogenesis. 
This means the vascular microenvironment can determine the pro/anti-
angiogenic state of the vasculature and highlights the complex and multiple 
steps that regulate angiogenesis. 
 
For angiogenesis to occur, space must be created through remodelling of 
the basement membrane, which is mediated by matrix metalloproteinase 
(MMP) proteolysis. This releases angiogenic factors stored within the matrix 
(Bergers et al., 2000) and activates growth factors through proteolytic 
cleavage (Iruela-Arispe & Davis, 2003). Vascular permeability is increased 
due to vascular endothelial-cadherin (VE-cadherin) and other junctional 
proteins become phosphorylated and internalised (Dejana 2004), which 
weakens junctions between endothelial cells. Increased permeability allows 
the release of plasma proteins, which deposits new extracellular matrix 
(ECM) proteins and release of angiogenic factors (Carmeliet 2000). The 
newly formed ECM provides a scaffold and a gradient of signals to guide 
endothelial cell migration (Carmeliet & Jain 2011). The ECM scaffold plays 
an active and important role in regulating growth factor signalling to 
migrating cells. For example, deleting the heparan sulphate proteoglycan 
(HSPG) retention motif in platelet derived growth factor B (PDGF-B) impairs 
pericyte recruitment (Lindblom et al. 2003). 
 
Disrupting the VE-cadherin junctions also sensitises endothelial cells to 
angiogenic stimuli by releasing growth factor receptors such as VEGFR2, 
and transcription factors such as β-catenin which are tethered in an inactive 
conformation (Figure 2) (Giannotta et al. 2013). This shows that pro-
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angiogenic signalling pathways can self-regulate through a positive 
feedback mechanism, which sensitises target endothelial cells and self-
amplify their own signalling pathways. 
 
Angiopoietin-2 (Ang-2) is produced in endothelial cells and promotes vessel 
remodelling, vascular permeability and angiogenesis in both physiological 
and pathological angiogenesis (Felcht et al. 2012). Ang-2 is rapidly released 
from intracellular organelles known as Weibel-Palade bodies in response to 
vascular permeability inducing factors (Fiedler et al. 2004). Storage of Ang-
2 and other factors within these organelles suggests that it enables 
endothelial cells to rapidly respond to permeability, inflammatory and 
thrombotic inducing agents (Metcalf et al. 2008). Ang-2 inhibits tyrosine 
kinase with immunoglobulin-like and EGF-life domains (Tie)2 signalling by 
competing with Ang-1 (Maisonpierre et al. 1997). This leads to activation of 
Foxo1 transcriptional activity which promotes vessel destabilisation and 
remodelling through upregulation of Ang-2 and MMPs (Kim et al. 2016). 
 
ECM remodelling, disruption of intercellular junctions and release of growth 
factors leads to the disruption of vascular homeostasis, and permits 
neovascularisation. The formation of new sprouting vessels is regulated by 
the selection of tip and stalk cells (Ribatti & Crivellato 2012). Tip cells have 
a polarized and motile phenotype, and migrate in the direction of angiogenic 
signals. Conversely, stalk cells have a high proliferative potential and are 
responsible for the de-novo formation of the vascular lumen, junction 
formation and basement membrane deposition. Selection of tip/stalk cell 
phenotype is determined at least in part by Notch signalling, which is 
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induced in stalk cells in response to increased VEGFR2 activation in tip cells 
(Phng & Gerhardt 2009). Acquisition of a tip or stalk cell phenotype 
determines how endothelial cells respond to various growth factors such as 
VEGF and TGF-β. Neuropilin-1 (Nrp1) is predominantly expressed in tip cells 
(Phng & Gerhardt 2009), where it attenuates the anti-angiogenic effect of 
TGF-β signalling by inhibiting Smad2/3 leading to increased pro-angiogenic 
signalling via Smad1/5/8 (Aspalter et al. 2015). 
 
Whilst sprouting angiogenesis is the most widely studied mechanism of 
angiogenesis, other physiological and pathological mechanisms exist. In 
physiological conditions, circulating endothelial progenitor cells (EPCs) can 
be recruited to differentiate into mature endothelial cells by vasculogenesis 
(Calzi et al. 2010), and existing vessels can be split to form multiple new 
vessels by intussusception (Gianni-Barrera et al. 2013). Whilst most 
neovascularisation results from locally proliferating endothelial cells through 
sprouting angiogenesis and intussusception, the contribution of EPCs should 
not be discounted since they are involved in both physiological and 
pathological angiogenesis (Calzi et al. 2010). 
 
1.2 Vascular stabilisation and maturation 
Generating stable and perfused vessels requires the recruitment of 
perivascular cells and the formation of endothelial cell junctions. The 
termination of vascular leakage enables the vessel to function and for 
perfusion to take place (Jain 2003). One area where pathological and 
physiological angiogenesis differ is during the stabilisation and maturation 
stages. Both of these play a crucial role in maintaining an intact and fully 
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functioning vascular network. This section will focus on the context of 
physiological angiogenesis for the purpose of discussing vascular 
stabilisation and maturation. 
 
1.2.1 Lumen formation 
Formation of the lumen is essential for allowing the newly formed vessel to 
perfuse the newly vascularized tissue, and occurs simultaneously with 
sprouting. Before lumen formation can take place VE-cadherin must form 
junctions between endothelial cells and provide polarity to the cytoskeleton 
which in turn provides organisation for lumen formation (Ribatti & Crivellato 
2012). Once formed, lumen diameter is dynamically regulated by; VEGF, 
endothelial-nitric oxide synthase (eNOS) and mural cells (Iruela-Arispe & 
Davis 2009) and is capable of determining blood pressure. 
 
1.2.2 Pericyte recruitment 
PDGF-B is secreted by endothelial cells undergoing angiogenesis and 
recruits PDGFRβ+ mural cells to the actively growing vessel (Hellström et 
al. 1999). PDGF-B appears to be predominantly expressed within the 
immature, leading edge of the vessel (Hellström et al. 1999), possibly 
confined to the tip cell (Armulik et al. 2011). Following PDGF-B/PDGFRβ 
mediated mural cell recruitment, endothelial cell derived TGF-β induces 
mural cell differentiation into pericytes or smooth muscle cells (Goumans et 
al. 2009). 
 
Mature pericytes then secrete Ang-1, which promotes endothelial cell 
stability by activating Tie2 signalling in endothelial cells (Armulik et al. 
 20 
2011). This promotes vascular quiescence in the newly formed vessel and 
leads to the resolution of the active vascular phenotype induced in response 
to Ang-2 signalling. The Ang-1/Tie2 signalling pathway promotes vascular 
homeostasis through Foxo1 phosphorylation (Daly et al. 2004), VE-cadherin 
(Lee et al. 2011) and occludin (Siddiqui et al. 2015) dephosphorylation and 
protection against advanced glycation endproduct (AGE) induced 
inflammatory injury (J. Zhao et al. 2015). 
 
1.2.3 Forming the mature vascular network 
A key stage in the maturation of a newly formed vascular network is for 
primitive vascular tubes formed during sprouting angiogenesis to undergo 
specialisation into arteries, capillaries and veins (Potente & Mäkinen 2017). 
Additional remodelling of the vascular plexus occurs through intussuception, 
coalescence, pruning, regression and alterations to lumen thickness to 
provide sufficient perfusion of the newly vascularised tissue (Ribatti & 
Crivellato 2012). The maturation of the vascular plexus is an essential step 
in physiological angiogenesis, and its absence is a hallmark of pathological 
angiogenesis (Jain 2003). 
 
1.3 Vascular Permeability 
The structure and function of the vascular endothelium varies according to 
the vascular bed, the type of vessel and temporal variations in physiological 
and pathological conditions. Permeability of the vascular endothelium is 
essential to its physiological function, enabling it to deliver nutrients and 
remove waste products and to permit the passage of larger objects such as 
cells, proteins and other larger molecules as required. During physiological 
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increases in permeability, elevated vascular permeability is limited and 
typically self-resolves (Nagy et al. 2008). This increase in permeability can 
be achieved through vesicular and vesiculo-vacuolar organelle (VVO), which 
are specialised organelles within certain endothelial cells which mediate 
transendothelial transport and the temporary dissolution of endothelial 
junctions, which permit transcellular and paracellular transport respectively 
(Claesson-Welsh 2015). 
 
Whilst the permeability of endothelial cells can be dynamically regulated 
according to the prevailing physiological and pathological state, the 
heterogeneity of the vascular endothelium determines basal levels of 
permeability. This is achieved through the differential expression of various 
organelles, such as caveolae and VVOs which regulate transcellular 
permeability and tight junctions which control paracellular permeability 
(Aird 2007). In the liver the endothelium is discontinuous and fenestrated 
which allows efficient transfer of large molecules, whilst the vascular 
endothelium in the brain is continuous with very low levels of caveolae and 
the presence of tight junctions between endothelial cells which form the 
highly selective blood-brain barrier (Potente & Mäkinen 2017). These 
structural differences between one of the most permeable vascular beds in 
the body and the most carefully regulated highlights how the endothelium 
becomes specialised according to the physiological requirements of different 
tissues. Therefore when investigating diseases that affect the vasculature it 
is important to consider the nature of the affected vascular network when 
designing experiments. 
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1.4 Vascular Endothelium in Pathology 
Whilst angiogenesis plays a key role in both physiology and development, it 
also plays a role in a variety of diseases such as cancer, obesity, ischemic 
retinopathies such as DR, and arthritis (Carmeliet 2003). Both pathological 
and physiological angiogenesis share many of the same mechanisms for the 
induction of angiogenesis; however, differences arise in their regulatory 
aspects and the lack of vascular maturation. 
 
Sustained angiogenesis and vascular permeability are often mediated 
through chronic inflammation as observed in diabetic retinopathy (Cheung 
et al. 2010), or through aberrant gene expression in cancer (Welti et al. 
2013). This leads to persistent pro-angiogenic/vascular permeability 
signalling. The result, is a vascular network which has expanded beyond 
what is required for tissue vascularisation, lacks appropriate mural cell 
coverage, has reduced basement membrane deposition, is highly permeable 
and is characterised by a low flow rate (Nagy et al. 2008). 
 
VEGF plays an important role in physiological angiogenesis, its role in 
pathological angiogenesis in solid tumours, AMD and DR has been well 
established (Nagy et al. 2007). The retina is one example of a tissue where 
VEGF plays a fundamental role in both physiology and pathology. VEGF is 
produced by multiple cell types, and is essential for development, 
homeostasis and visual function (Sene et al. 2015). In disease, VEGF is 
induced by hypoxia, predominantly through transcriptional activity of HIF-
1α in addition to pro-inflammatory signalling induced by the innate and 
adaptive immune system (Sene et al. 2015). There is extensive 
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heterogeneity in macrophage phenotype, where the phenotype of the 
macrophage population varies during different stages of angiogenesis and 
the presence of various cytokines in the local microenvironment (Corliss et 
al. 2016). This affects the level of angiogenesis and vascular remodelling by 
altering the secretome of the local macrophage population, with varying 
levels of VEGF, MMPs, PDGF and other growth factors depending on the 
macrophage population (Spiller et al. 2014; Corliss et al. 2016). The 
adaptive immune system can also enhance angiogenesis (Sene et al. 2015), 
recruited T cells secrete IL-17 which enhances the activity of VEGF and 
other growth factors (Takahashi et al. 2005).  
 
Increased VEGF production during physiological conditions such as wound 
healing is followed by a resolution of the hypoxic or inflammatory stimuli 
after the tissue has been appropriately vascularised. Sustained hypoxia and 
inflammation in DR leads to the upregulation of VEGF, which promotes 
inflammation, vascular permeability and eventually angiogenesis (Penn et 
al. 2008). In the retina, neuronal cells express high levels of VEGFR2, which 
negatively regulates angiogenesis by sequestering VEGF (Okabe et al. 
2014). Since neuronal cell loss has been previously reported in diabetic 
mice (Martin et al. 2004), this may contribute to the increased 
bioavailability of VEGF in the diabetic retina resulting in increased activation 
of VEGF signalling in the retinal vasculature. Whilst this theory has not been 
proven, creation of an inducible, cell specific Vegfr2 KO mouse would allow 
expression of Vegfr2 to be switched off in an adult mouse, thus avoiding 
issues arising during development. If VEGFR2 were to play a role in 
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reducing the availability of VEGF, in mice where Vegfr2 was conditionally 
deleted, more free Vegf would be present in the retina. 
 
During sustained inflammation, modulation of VEGF induced angiogenesis 
by inflammatory mediators is likely to alter the biology of endothelial cells 
resulting in pathological angiogenesis and vascular permeability. Therefore 
whilst anti-VEGF therapeutics are widely used in the clinic for the 
management of pathological angiogenesis, the role of other mediators may 
explain the limited effectiveness of VEGF blockade in DR and other vascular 
diseases, due to the activity of other compensatory pathways.  
 
Foxo1 has been implicated in both physiological (Daly et al. 2004) and 
pathological (Behl et al. 2009) angiogenesis. IL-6 activates signal 
transducer and activator of transcription 3 (STAT3) in endothelial cells and 
promotes poorly regulated and pericyte deficient neovessels (Gopinathan et 
al. 2015). Whilst this has not been shown in endothelial cells, pSTAT3 
enables the nuclear translocation of Foxo1 in T cells (Oh et al. 2012). This 
shows that both physiological and pathological mediators of angiogenesis 
may regulate Foxo1. The increased expression of Ang-2 driven by the Ang-
2/Foxo1 signalling is a key feature of vascular remodelling. Ang-2 
upregulation causes pericytes to detach and migrate away from endothelial 
cells. 
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2 Retinal vasculature and neurovascular unit 
The mammalian retina is delicate and requires a carefully controlled 
microenvironment (Klaassen et al. 2013). It has one of the highest 
metabolic demands in the whole body, due to the energy required by 
photoreceptors for visual function (Arden et al. 2005). Therefore the retinal 
vasculature must provide adequate perfusion to the retina to deliver 
sufficient metabolites and oxygen whilst not interfering with light detection.  
 
The neurovascular unit links the retinal vasculature with retinal neurons, 
and consists of endothelial cells closely associated with pericytes, astrocytes 
and Müller cells, which regulate the growth and stability of the vascular 
network and maintains the inner blood-retinal barrier (BRB) (Stem & 
Gardner 2013; Moran et al. 2016; Park et al. 2017), the choroidal 
vasculature and the retinal pigment epithelium (RPE) make up what is 
known as the outer BRB and will be discussed later. These intimate 
associations allow the fine-tuning of blood flow to meet the precise 
metabolic demands of the neurosensory retina (Stem & Gardner 2013; Kur 
et al. 2012). The unique nature of the neurovascular unit contributes to the 
well-regulated BRB, and the role of the different cells that make up the 
neurovascular unit and how they maintain low rates of vascular 
permeability will be discussed below. 
 
2.1 Pericytes 
Extensive pericyte coverage in the retinal vasculature is believed to be 
associated with the tight control of vascular permeability (Armulik et al. 
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2011). Pericytes are intimately associated with endothelial cells with a 
shared basement membrane (Ribatti et al. 2011), physical attachments to 
the endothelium by neural cadherin (N-cadherin) junctions (Tillet et al. 
2005), and gap junctions which provide an intercellular pore enabling direct 
cell-cell communication (Bobbie et al. 2010).  
 
Pericytes and endothelial cells are linked by common paracrine signalling 
pathways which play a role in both physiological and pathological regulation 
of the retinal vasculature (Sweeney et al. 2016). PDGF-B mediated pericyte 
recruitment to the sprouting endothelium is one of the first endothelial-
pericyte signalling pathways activated and is essential for development of 
the mature retinal vasculature (Park et al. 2017; Ogura et al. 2017; 
Hellström et al. 1999). Pericyte attachment to newly formed vessels 
requires N-cadherin, and N-cadherin knock out (KO) mice die in utero (Tillet 
et al. 2005) and antagonising N-cadherin in adult mice enhances vascular 
leakage (Turley et al. 2015). This indicates that N-cadherin has important 
roles in both development and maintaining integrity of the vasculature.  
 
Whilst pericytes and pericyte-derived Ang-1 play an essential role in 
vascular development and protection from disease-associated insult 
(Jeansson et al. 2011; J. Zhao et al. 2015; Ogura et al. 2017), they appear 
to be redundant for maintaining retinal vascular quiescence (Park et al. 
2017). Additionally in the retina, pericytes aren’t the source of Ang-1 (Park 
et al. 2017). This suggests that pericytes and Ang-1 are primarily involved 
in the downregulation of signalling pathways that disrupt vascular 
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homeostasis and Ang-1 may be redundant for maintaining vascular 
quiescence.  
2.2 Macroglia 
Müller cells and astrocytes are the two types of macroglia found in the 
retina, where they associate with neurons to maintain normal physiological 
function and homeostasis (de Hoz et al. 2016). They form a direct link 
between the neurons and blood vessels which facilitates the transfer of 
nutrients and waste products and regulate blood flow in response to 
neuronal activity (de Hoz et al. 2016). In addition, the coupling of both 
Müller cells and astrocytes enhances the integrity of the BRB (Abbott et al. 
2006; Tout et al. 1993) which is crucial for maintaining the carefully 
regulated microenvironment. Since the neurovascular unit which is only 
found in the brain and retina has such a carefully regulated barrier, this 
implies that macroglia enhance the barrier properties of the vascular 
endothelium beyond what can be achieved by pericytes alone. 
 
The unique properties of the retinal vasculature carefully maintain the 
neural retinal microenvironment to ensure visual function. Cells of the 
neurovascular unit secrete paracrine mediators and directly interact with 
endothelial cells. Pericytes, Müller cells and astrocytes all have functional 
capabilities that are designed to counter vascular insults such as 
inflammation, oxidative stress and hypoxia. For example Müller cells have 
an enriched supply of anti-oxidants which have a neuroprotective effect by 
reducing oxidative stress, preventing damage to neurons (de Hoz et al. 
2016). Pericytes also modulate the response to pro-inflammatory and 
permeability-inducing agents through paracrine signalling (Park et al. 
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2017). Whilst the cells of the neurovascular unit are able to adapt to acute 
stresses, chronic conditions such as diabetes override the protective 
activities of the neurovascular cells. This can induce an ‘inflammatory 
switch’ resulting in chronic inflammation. This manifests itself in several 
ways such as pericyte loss (Pfister et al. 2008; Park et al. 2014), astrocyte 
dysfunction (Ly et al. 2011) and secretion of pro-inflammatory and vascular 
permeability-inducing agents by Müller cells (Yafai et al. 2013). The 
pathophysiology of the retinal vasculature and the neurovascular unit and 
its contribution to the altered microenvironment in diabetic retinopathy will 
be discussed in further detail later in this chapter. 
 
2.3 Retinal endothelial cells 
2.3.1 Inter-endothelial cell junctions 
The retinal vascular endothelial cell is adapted to maintain a tight barrier 
between the blood and the retinal tissue. It achieves this through the 
abscence of fenestrations, a low number of transport vesicles and the 
presence of tight junctions (Klaassen et al. 2013). There are three types of 
junctions which contribute to the blood-retinal barrier; gap junctions, 
adherens junctions and tight junctions (Klaassen et al. 2013) (Figure 2). 
 
The adherens junction is one of the first intercellular junctions to form 
during sprouting angiogenesis (Ribatti & Crivellato 2012) and is primarily 
made up of VE-cadherin which joins and stabilises endothelial cells. 
Intercellular VE-cadherin junctions are dynamic and undergo frequent 
reorganisation, regulate intercellular signalling and play a key role in tight 
junction formation by inducing claudin-5 expression (Taddei et al. 2008). 
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Therefore, the formation of this initial junction between endothelial cells is 
crucial for producing a stable vessel wall and promoting BRB integrity. 
 
Endothelial tight junctions are spread throughout the intercellular junction, 
with increased numbers of inter-endothelial tight junctions at the cell-cell 
interface correlating with increased control of vascular permeability 
(Klaassen et al. 2013). Claudins-1, 2 and 5 and occludin (Hirase et al. 
1997) are the main proteins that make up the inter-endothelial tight 
junction. However, claudin-5 is the most highly expressed tight junction 
protein in endothelial cells by several orders of magnitude (Ohtsuki et al. 
2007). Other endothelial tight junction proteins include junctional adhesion 
molecules (JAMs) and endothelial-cell specific adhesion molecule (ESAM) 
(Klaassen et al. 2013), however, their functions in tight junction and barrier 
integrity are less well understood than the claudins and occludin. The 
claudins, occludin, JAMs and ESAM are all linked to the cytoskeleton by the 
intercellular tight junction protein zonula occludens-1 (ZO-1), which 
regulates the tight junction protein complex and associated cytoskeleton. 
This in turn regulates cell morphology around intercellular junctions and 
maintains barrier formation (Tornavaca et al. 2015). 
 
Endothelial tight junction proteins (occludin, claudins-1, 2 and 5) are 
generally not downregulated during disruption of the BRB, with claudins-2 
and 5 being upregulated (Luo et al. 2011) in what may be a compensatory 
mechanism. However, in the mouse oxygen induced retinopathy (OIR) 
model, the distribution of tight junctions proteins were altered (Figure 2) 
and they were no longer enriched at endothelial cell junctions (Luo et al. 
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2011). This indicates that the localisation of tight junction proteins at the 
cell membrane is more important than their absolute abundance. A 
decrease in ZO-1, which regulates tight and adherens junction organisation 
is associated with severe vascular leakage (Komarova et al. 2017). This 
indicates that the vascular endothelium may tolerate a reduction in tight 
junction protein content, but the correct positioning of tight junction 
proteins at the endothelial cell junction and their interaction with the 
cytoskeleton are crucial for maintaining junctional integrity. 
 
Figure 1: Hierarchy of inter-endothelial cell junctions. VE-cadherin is 
a ubiquitously expressed junctional protein and is essential for basal 
permeability and stability of the vascular endothelium. N-cadherin is 
expressed at endothelial-pericyte junctions, and as such is associated with 
tighter and more specialised vascular beds. Tight junctions are the most 
specialised and least widespread endothelial junction. Additionally tight 
junction formation is dependent on the presence of adherens junctions.  
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Tight junctions and adherens junctions both play important roles in 
maintaining the BRB, and different types of junctions exert distinct effects 
in the regulation of vascular permeability. Adherens junctions mediated by 
VE-cadherin are the first junctions to form between endothelial cells and 
their role in initiating the formation of other endothelial cell junctions means 
this can be considered a ‘master regulator’ of vessel stability (Figure 1) and 
barrier function. Downstream of VE-cadherin junction formation is N-
cadherin, which mediates interactions between endothelial cells and mural 
cells. 
 
The role of N-cadherin in pericyte coverage means we can consider the 
degree of N-cadherin mediated adherens junction formation to be linked 
with specialisation of the endothelium. The barrier properties of tight and 
adherens junctions also differ and reflect the requirements for increased 
control of vascular permeability depending on the vascular bed. Adherens 
junctions are impermeable to albumin and other large macromolecules (~70 
kDa) (Villasante et al. 2007), whilst tight junctions regulate the 
permeability of much smaller molecules (<1 kDa) (Bazzoni 2006), and ions 
based on their charge (Díaz-Coránguez et al. 2017). 
 
Whilst the cadherins are ‘hierarchically’ more important in regulating 
vascular permeability (Figure 1), tight junctions also play a crucial role in 
specialised vascular beds where the passage of solutes to delicate 
neurosensory tissue must be carefully controlled. Additionally, spatial 
regulation of both adherens and tight junction protein distribution is 
essential to their roles in maintaining endothelial barrier function, perhaps 
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more so than their absolute level of expression as alluded to by analysis of 
occludin in the mouse model of oxygen-induced retinopathy (a model of 
ischemia induced neovascularisation) (Barber et al. 2000).  
 
2.3.2 Transcellular permeability 
Most transport across the retinal endothelium is mediated either by 
membrane bound receptors or carrier proteins, and with the exception of 
nutrients, is energy dependent. These membrane bound transporters have 
distinct functions such as; the transport of nutrients, the exchange of ions 
and the efflux of drugs and potentially toxic molecules which diffuse across 
the plasma membrane (Klaassen et al. 2013). Due to the restriction of free 
diffusion between endothelial cells in the retinal vasculature, specific carrier 
proteins mediate the transport of nutrients such as hexoses, amino acids, 
nucleosides and other metabolic precursors across the lumen via facilitated 
diffusion (Zlokovic et al. 2008). 
 
Glucose transporter-1 (GLUT-1) is probably one of the most important 
nutrient carriers in the retina as glucose is the most important nutrient for 
neuronal tissue (Chertov et al. 2011) and it is expressed on both the 
luminal and abluminal sides of the retinal endothelial cell (Takata et al. 
1992). GLUT-1 activity is insulin-independent and is therefore dependent on 
blood glucose levels (Bakker et al. 2009). Asymmetrical distribution of 
GLUT-1 towards the abluminal side of the endothelial cell helps maintain a 
concentration gradient between the vasculature and retinal tissue (Zlokovic 
et al. 2008). When retinal endothelial cells are exposed to elevated levels of 
glucose, the rate of glucose transport is increased (Busik et al. 2002) 
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without affecting the rate of glucose consumption by endothelial cells (Busik 
et al. 2008). This means that in hyperglycaemic conditions such as 
diabetes, increased glucose transport across the endothelium exposes 
retinal cells such as photoreceptors to high glucose levels, which contributes 
to the pathology of diabetes, and that hyperglycaemia has effects beyond 
the vascular endothelium. 
 
Larger macromolecules cross the retinal endothelium through specialised 
vesicles, known as caveolae, in a receptor-dependent or -independent 
fashion (Klaassen et al. 2013). Unlike other vascular beds, caveolae are the 
only organelle which facilitate transcellular transport in the retinal 
endothelium (Hofman et al. 2000). Whilst the paper by (Hofman et al. 
2000) showed by electron microscopy that VEGF induced formation of 
caveolae but not fenestrae in the retinal endothelium, one cannot rule out 
the possibility that other growth factors may induce the formation of 
fenestrae, however, this is unlikely to occur. Plasmalemma vesicle-
associated protein (PLVAP) is essential for the formation of caveolae (Figure 
2), where it plays an important role in forming the structure of the caveolae 
(Guo et al. 2016). It is upregulated in diseases associated with angiogenesis 
and vascular leakage (Guo et al. 2016). Since VEGF plays a key role in 
mediating vascular permeability, intravitreal administration of VEGF to the 
mouse retina elevated transcellular vascular permeability through increased 
PLVAP dependent caveolae transport rather than fenestration or vesiculo 
VVO formation (Hofman et al. 2000). This indicates that caveolae mediate 
transcellular permeability in the retinal vasculature in both physiological and 
pathological conditions. 
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Increased permeability of the retinal vasculature can be increased through 
paracellular and transcellular routes. In diabetic retinopathy perturbations 
occur to regulators of both routes of vascular permeability (Navaratna et al. 
2007), with VEGF promoting both transcellular permeability through PLVAP 
upregulation (Wisniewska-Kruk et al. 2016) and the phosphorylation of tight 
junction proteins (Antonetti et al. 2012) (Figure 3). Whilst the contribution 
of adherens and tight junction loss to increased vascular permeability has 
been more widely investigated, the role of transcellular permeability should 
not be discounted and is likely to play an equally important role. 
 
2.4 The choroidal vasculature and the outer-BRB 
In contrast to the retinal vasculature, the choroid is much more extensively 
vascularised and the choroidal vasculature is leaky and fenestrated (Aird 
2007). Whilst inter-endothelial junctions regulate vascular permeability in 
the retinal vasculature and makes up the inner-BRB, the outer-BRB is 
regulated by the RPE (Fig 2). Tight junctions between RPE cells and the 
presence of specific transporters control the passage of water, solutes and 
other molecules into the retina, which is vital for the maintenance of retinal 
homeostasis (Benedicto et al. 2017).  
 
Whilst there is some evidence of outer-BRB disruption in diabetes, such as 
dysfunction of the outer retina (Samuels et al. 2014), there is limited 
evidence of outer-BRB derived leakage only occurs very late in the 
streptozotocin mouse, with evidence of leakage occurring at earlier time-
points in the diabetic rat (Simó et al. 2010). Examination of the RPE in 
streptozotocin-induced diabetic mice 2-months after diabetes induction and 
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mice fed a high fat diet for 5 weeks revealed no changes to the integrity of 
the RPE (data not shown). Therefore this avenue of inquiry was not further 
pursued. Examination of the RPE in other models of diabetes, which present 
a more severe phenotype may have identified a disruption to the RPE which 
may have identified scope for further research. Evidence from diabetic 
patients shows that vascularisation of the choroid is decreased in diabetic 
retinopathy (Gupta et al. 2017). This could contribute to oxidative stress in 
the retina as the capacity of the choroidal vasculature to provide nutrition to 
the retina is likely to be diminished.  
 
Figure 2: a schematic representing the blood-retinal barriers 
(Forrester & Xu 2012). Tight junctions regulate the passage of various 
molecules into the retina, the intra-retinal vasculature contains tight 
junctions between endothelial cells, whilst the RPE has tight junctions 
between cells which regulates the flow of molecules derived from choroidal 
vasculature.  
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Figure 3: The quiescent and active vasculature. A: the quiescent 
vasculature has intact endothelial junctions and low levels of caveolae and 
associated low levels of PLVAP expression, a key structural protein required 
for cavaeolae function leading to reduced paracellular and transcellular 
permeability. B: the activated endothelium has weakened endothelial 
junctions and increased numbers of caveolae, which increases permeability. 
This is due to pericyte detachment and altered gene expression.  
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3 Diabetes and diabetic retinopathy 
Diabetes manifests itself either through the loss of insulin production 
following destruction of pancreatic β-cells (Type 1 Diabetes) or development 
of insulin resistance (Type 2 Diabetes). Both types of diabetes lead to 
elevated blood glucose, which has a range of impacts on different organs of 
the body leading to increased morbidity and mortality. Diabetes is 
associated with multiple microvascular and macrovascular complications, 
but diabetic retinopathy is the most common complication associated with 
the microvasculature and the retina.  
 
One third of the 246 million diabetic patients have some signs of diabetic 
retinopathy with a third of these having signs of severe retinopathy 
(Cheung et al. 2010). Diabetic retinopathy manifests itself in two stages, 
the proliferative and non-proliferative stage. The first is the early non-
proliferative diabetic retinopathy (NPDR), which is characterized by 
microaneurysms, lipid exudates, haemorrhage, nerve fibre damage, 
basement membrane thickening, pericyte dropout, vascular regression and 
formation of tortuous vessels. Proliferative diabetic retinopathy (PDR) 
typically follows NPDR and is characterized by neovascularization, retinal 
detachment and decreased visual acuity. Diabetic macular oedema (DMO) 
may occur at either stage and is associated with vascular leakage and 
retinal thickening (Antonetti et al. 2012)  
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Figure 4: The multiple stages and mechanisms of pathophysiology 
of diabetic retinopathy. Adapted from (Stitt et al. 2016) & (Ly et al. 
2011). A: Fundus image (left) and fluorescein angiogram (right) from a 
patient with NPDR. The fundus image reveals the presence of 
microaneurysms (arrowheads) and areas with inflammatory infiltrates 
(arrows). Fluorescein angiogram shows the microaneurysms more clearly 
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due to the extravasated fluorescein and unperfused ischemic areas (white 
arrow). B: Fundus image (left) and fluorescein angiogram from a patient 
with PDR. During PDR, the severity of the vascular complications have 
increased with increase haemorrhage (black arrow) and the formation of 
tortuous neovessels (black arrowhead). The fluorescein angiogram 
highlights increased areas of hypoxia (white arrow) with increased areas of 
vascular leakage (white arrowhead) compared to the NPDR patient in A. C: 
Sections from non-diabetic and diabetic donor eyes analysed for apoptosis 
reveals an increased number of apoptotic cells in the diabetic retina. D: 
Sections from non-diabetic and diabetic donor eyes stained for GFAP reveal 
increased GFAP staining in the Müller cells, which is indicative of reactive 
gliosis and retinal stress. E: GFAP staining in a flatmounted control and 
diabetic rat retina (Ly et al. 2011). Diabetes reduces the total number of 
astrocytes and the number of interactions with the retinal vasculature. 
 
Progression in the severity of diabetic retinopathy is common in the long 
term. In a 14 year population based study to measure the progression and 
incidence of diabetic retinopathy, 86% of patients had an increased severity 
grading in retinopathy, from which 26% progressed to DMO and 37% 
progressed to PDR (Klein et al. 1998). It is possible that some patients did 
not progress to PDR due to a satisfactory management of diabetic 
retinopathy. The high incidence of diabetic retinopathy in diabetic patients 
and the high rate of progression in the severity of diabetic retinopathy show 
that the clinical relevance of diabetic retinopathy is becoming increasingly 
important since the number of diabetic patients is increasing, which is likely 
to lead to a greater number of patients at risk of vision loss. This highlights 
a need for improved understanding of pathophysiology, identification of new 
therapeutic targets and improved clinical management of patients. 
  
 40 
3.1 Current therapeutic strategies 
A therapeutic target is anything within a living organism with which can be 
modulated resulting in a functional change in the context of a given disease. 
For example, VEGF is a therapeutic target for diabetic retinopathy and many 
other diseases (Zaghloul et al. 2009), and its activity can be modulated, for 
example by blocking antibodies which prevent it functioning as a signalling 
molecule. Since VEGF blockade has several side effects and limitations 
which will be discussed below, it can be considered a therapeutic target with 
limited (although still potent) efficacy. 
 
VEGF blockade has been the best therapeutic strategy to offer 
improvements to DR patients vision, compared to laser therapy and 
corticosteroids (Brown et al. 2013; Elman et al. 2012; The Diabetic 
Retinopathy Clinical Research Network 2015). Aflibercept is the latest anti-
VEGF agent, which is the current first line therapeutic for the management 
of diabetic retinopathy (Heier et al. 2016). Despite the benefits of anti-VEGF 
therapies there are several side effects which result from this therapy, 
including intraocular inflammation, retinal detachment, intraocular pressure 
elevation, haemorrhage and systemic effects (Falavarjani & Nguyen 2013). 
Additionally VEGF blockade is not always effective in the long term, with 
46% of patients requiring laser photocoagulation after 2 years and 40% 
seeing no improvement in visual acuity (Elman et al. 2012). Another 
limitation of VEGF blockade for the treatment of DR is that it can only be 
used when the vascular symptoms of DR appear and not before. Therefore 
a lack of treatments for the non-proliferative stage of DR present a major 
unmet clinical need. 
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Figure 5: Current therapeutic strategies for the management of 
diabetic retinopathy. VEGF blockade is the current first line therapeutic 
used in the clinic after evidence of macular oedema is observed. Currently 
there is no therapeutic which can be administered prior to the development 
of oedema or neovascularisation. Laser photocoagulation is a second line 
therapeutic used in patients who don’t respond, develop resistance or have 
other contraindications which prevent the use of VEGF blockade. Vitroretinal 
surgery is only used in advanced cases. 
 
Laser photocoagulation, is the current second line therapeutic used in the 
clinic. The aim of laser photocoagulation is to stabilise vision rather than 
offer improvements. This can only be utilised after the disease progresses 
into the macula. Vitreoretinal surgery is used to manage the late stage of 
the disease where blood leakage occludes vision and tissue scarring is 
present. 
 
Corticosteroids have been used to target increased inflammation typically 
associated with diabetic retinopathy. Despite the important role of 
inflammation in the pathology of diabetic retinopathy, treatment with 
steroids has shown limited success with only temporary benefits and 
various side effects including cataracts and glaucoma (Grosso & Panico 
2009). 
 
 
 
Anti-VEGF agents Laser Photocoagulation Corticosteroids
Vitroretinal 
Surgery
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3.2 Metabolic Changes  
Glucose uptake by endothelial cells from the blood is mediated by GLUT-1, 
an insulin independent glucose transporter (Bakker et al. 2009). When 
diabetes is poorly controlled, intracellular glucose levels increase in line with 
blood glucose levels above normal physiological levels. This leads to 
increased glycolysis and accumulation of intermediate glucose metabolites 
and altered glucose metabolism (Giacco & Brownlee 2010). 
 
3.2.1 Altered glucose metabolism 
During diabetes there is increased activity of the polyol pathway, where 
glucose and its accumulated metabolites are converted to sorbitol by aldose 
reductase which utilises nicotinamide adenine dinucleotide phosphate 
(NADPH) (Mathebula 2015). NADPH acts as a reducing agent and is 
required for the regeneration of cellular antioxidants. 
 
During diabetes, the hexosamine biosynthesis pathway is increased due to 
fructose 6-phosphate accumulation (Buse 2006). This leads to O-Linked β-
N-Acetylglucosamine (O-GlcNAc) post-translational modifications to proteins 
(Semba, R., et al. 2014). This can modulate gene expression and signalling, 
by altering transcription factors such as specificity protein 1 (Sp-1) and 
inhibiting eNOS activity (Giacco & Brownlee 2010). 
 
3.2.2 AGE accumulation 
Accumulation of intermediate glucose metabolites and altered glucose 
metabolism, promotes the formation of advanced glycation end products 
(AGEs) resulting in AGE deposition on proteins (Yamamoto, Y. & Yamamoto, 
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H., 2012). AGEs can alter the vasculature by several different mechanisms 
such as modifying proteins involved in gene transcription, modifying ECM 
proteins and integrin signalling, modification of circulating proteins and 
activation of various AGE receptors, with the most important being the 
receptor for advanced glycation end products (RAGE) (Stirban et al. 2014). 
STAT3, nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB), 
activator protein-1 (AP-1) and Forkhead box (Foxo) transcription factors are 
all activated downstream of RAGE activation (Stirban et al. 2014), which 
shows this is to be an important mediator of pro-inflammatory signalling. 
RAGE is widely expressed on many cell types and mediates the early stages 
of pathology in diabetic retinopathy (Barile et al. 2005), by promoting 
oxidative stress, inflammation and apoptosis (Stitt 2010). In-vitro studies 
have demonstrated that advanced glycation end product – bovine serum 
albumin (AGE-BSA) induces endothelial cell proliferation and VEGF 
production (Mamputu & Renier 2004). However, long term exposure to AGE 
induced signalling in the diabetic retina may eventually lead to endothelial 
cell death induced by inflammation and oxidative stress.  
 
Altered glucose metabolism has a wide range of effects on the retina and 
the retinal vasculature, including altered gene expression, inflammation and 
oxidative stress. Reciprocal interactions between inflammation and oxidative 
stress exacerbate aberrant signalling pathways, which contribute to hypoxia 
and vascular dysfunction in diabetic retinopathy. 
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3.3 Pathophysiology 
Since the primary symptom of diabetes is elevated blood glucose it is easy 
to assume that endothelial cell dysfunction is the first event in the 
pathogenesis of diabetic retinopathy and other microvascular complications 
of diabetes (Bakker et al. 2009). Whilst diabetic retinopathy has a clear 
vascular phenotype, neuroretinal symptoms appear before vascular 
complications arise (Antonetti et al. 2006). The pathophysiological features 
of diabetic retinopathy are summarised in (Fig. 5), which highlights how 
inflammation, neurovascular changes and vascular dysfunction are related 
and contribute to diabetic retinopathy. All of these features of diabetic 
retinopathy will be discussed in further detail later in this thesis. 
Considering how pericytes, glial and endothelial cells are intimately 
associated within the neurovascular unit, it’s unsurprising that endothelial 
cell dysfunction may not be the first event in the pathophysiology of 
diabetic retinopathy. 
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Figure 6: A summary of the mechanisms of pathophysiology in 
diabetic retinopathy (Lechner et al. 2017). This highlights how multiple 
aspects of the pathophysiology of diabetic retinopathy are interlinked and 
act together to increase the severity of this disease leading to the risk of 
vision loss. 
 
3.3.1 Astrogliosis 
Astrocyte dysfunction occurs prior to the development of Müller cell gliosis 
in the streptozotocin induced diabetic rat (Ly et al. 2011). Additionally 
retinal ganglion cell death (Kern & Barber 2008), hypoxia  and vascular 
leakage in the superficial plexus (Ly et al. 2011) occur early in diabetic 
retinopathy. In diabetic rats, reduced astrocyte number, processes and 
connexin-43 expression occurred early in diabetes (Ly et al. 2011). This 
implies that astrocyte dysfunction may be responsible for disruption of the 
neurovascular unit in this plexus. 
 
High glucose induces astrocyte proliferation in vitro (Shin et al. 2014), 
which may drive a transient increase in astrocyte number early in diabetic 
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retinopathy (Ly et al. 2011). Similar to Müller glia, this could be a protective 
response to increased retinal stress to protect retinal neurons. High glucose 
alters astrocyte migration and morphology (Shin et al. 2014) which may 
explain the reduction in astrocytic processes which are involved in the 
interaction with endothelial cells (Figure 3 E). During astrogliosis, there is 
also an increase in secreted inflammatory cytokines such as IL-6 and 
monocyte chemoattractant protein 1 (MCP-1) (Sorrentino et al. 2016), 
which is mediated by oxidative stress-induced p38 mitogen activated 
protein kinase (MAPK) signalling (Nahirnyj et al. 2013). Altered astrocyte 
proliferation and morphology was shown to be attenuated by anti-oxidant 
treatment in vitro (Shin et al. 2014). This shows that oxidative stress 
appears to be a key driver of astrocyte dysfunction in diabetes. Astrocyte 
biology is also influenced by Ang-2 in diabetes. Upregulation of Ang-2 
expression in diabetic retinopathy promotes astrocyte apoptosis via integrin 
signalling (Yun et al. 2016). Therefore in addition to its role in pericyte loss, 
Ang-2 also contributes to a reduction in astrocyte number. This shows that 
multiple aspects of the diabetic microenvironment alter astrocyte behavior 
and their interactions with the vasculature. 
 
3.3.2 Müller cell gliosis 
In diabetic retinopathy Müller cells undergo various changes such as; 
increased glial fibrillary acidic protein (GFAP) expression, reduced glutamine 
synthetase expression, disrupted neurotransmitter uptake and cytokine 
secretion (Kur et al. 2012). GFAP expression is associated with reactive 
gliosis, which occurs in response to retinal stress (Bringmann & Wiedemann 
2012). Reactive gliosis in Müller cells occurs later in diabetic retinopathy 
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than astrocyte dysfunction, and is associated with reduced photoreceptor 
activity (Ly et al. 2011). In diabetes, AGE/RAGE signalling in Müller cells 
(Stitt et al. 2016) and hypoxia (Xin et al. 2013) promotes Müller cell gliosis. 
Whether hypoxia occurs prior to gliosis or secondary to inadequate blood 
flow due to reduced interaction between neurons and the vasculature 
(neurovascular coupling) is is unknown. Regardless of the mechanism, 
hypoxia induced signalling is a key mechanism for Müller cell induced 
vascular permeability (Xin et al. 2013; Wang et al. 2010), either through 
the release of growth factors or signaling through cell-cell junctions, 
possibly connexin-43 (Bobbie et al. 2010). 
 
During acute periods of retinal stress, the secretion of pro-inflammatory 
mediators such as MCP-1 and tumour necrosis factor-α (TNF-α) during 
reactive gliosis helps recruit monocytes and microglia to areas of retinal 
stress (Bringmann & Wiedemann 2012). Sustained secretion of these pro-
inflammatory cytokines during extended periods of gliosis leads to chronic 
inflammation (Yu et al. 2015). Müller cells also secrete pro-angiogenic and 
vascular permeability inducing agents VEGF (Bai et al. 2009), fibroblast 
growth factor 2 (FGF-2) (Yafai et al. 2013) and angoipoietin like 4 (Angptl-
4) (Xin et al. 2013). VEGF and FGF-2 are neuroprotective and promote 
photoreceptor survival, by activating pro-survival signaling pathways (Yafai 
et al. 2013). However, sustained secretion of these growth factors promotes 
chronic inflammation and vascular leakage. Additionally disruptions to 
nutrient and waste exchange may contribute to the induction of oxidative 
stress in photoreceptors (Du et al. 2013), exacerbating the chronic 
inflammatory microenvironment. 
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3.3.3 Pericyte loss 
Pericyte loss in diabetic retinopathy is one of the first vascular defects to 
occur (Stitt et al. 2016). Whilst the ratio of pericytes to endothelial cells in 
the retina is one of the highest throughout the vasculature (Cuthbertson & 
Mandel 1986), even small reductions in pericyte coverage may lead to 
vascular dysfunction (Pfister et al. 2008; Hammes et al. 2004). Therefore 
even minor mechanisms of pericyte loss may be clinically relevant to 
diabetic retinopathy, as the high pericyte-endothelial cell ratio may be 
required for the maintenance of the retinal vasculature.  
 
Several publications have reported that pericyte loss in DR is mediated by 
Ang-2 (Hammes et al. 2004), possibly acting through multiple mechanisms. 
For example, Ang-2 may induce pericyte loss by inducing pericyte migration 
(Pfister et al. 2008) or apoptosis (Park et al. 2014).  
 
Pericyte loss leads to impaired BRB integrity, (Park et al. 2017) increased 
risk of developing a pro-inflammatory state in the endothelial cells such as 
upregulation of IL6 and TNFα expression, leukocyte adhesion and infiltration 
(Ogura et al. 2017). As pericytes play a key role in the neurovascular unit 
by linking endothelial cells with astrocytes and glial cells, a loss of pericyte 
coverage may be expected to play a key role in disruption of the 
neurovascular unit (Klaassen et al. 2013). 
 
3.3.4 Endothelial cell dysfunction 
In diabetic retinopathy, disruption of the quiescent and selectively 
permeable endothelium (Fig. 2 B) occurs primarily due to paracrine 
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mediators from two sources, the cells of the neurovascular unit (Figure 6) 
and circulating leukocytes that adhere to the vessel wall. Disruption of the 
neurovascular unit leads to insufficient blood flow (de Hoz et al. 2016), 
reduced barrier integrity (Gardner et al. 1997), endothelial cell 
inflammation and monocyte recruitment (Park et al. 2017; Ogura et al. 
2017). Leukocyte adhesion molecules are upregulated following the release 
of inflammatory mediators from cells of the neurovascular unit (Yu et al. 
2015). Impaired neurovascular coupling and the secretion of pro-
inflammatory factors promote pro-inflammatory and permeable conditions 
in the retinal vasculature. 
 
Figure 7: The neurovascular unit of the retina (Antonetti et al. 
2006). Light sensing retinal neurons are physically linked to the retinal 
vascular endothelium by Muller cells and Astrocytes, which dynamically 
regulate blood flow according to the metabolic demands of the retina.  
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3.3.4.1 Disruption to endothelial cell junctions 
Endothelial adherens junctions are disrupted by VEGF dependent VE-
cadherin phosphorylation and internalization (Gavard & Gutkind 2006) and 
MMP mediated proteolysis of the extracellular domain of VE-cadherin 
(Navaratna et al. 2007). These two mechanisms indicate that multiple 
mechanisms are involved in the breakdown of the BRB in diabetic 
retinopathy. Aside from its role in maintaining inter-endothelial cell 
junctions, VE-cadherin associates with VEGFR2 (Giannotta et al. 2013) and 
the TGF-β receptor complex (Rudini et al. 2008) which suppresses both 
receptors signalling pathways by tethering these receptors in an inactive 
conformation. Additionally VE-cadherin prevents β-catenin entering the 
nucleus and inactivates Foxo1 by phosphorylation (Taddei et al. 2008). 
Therefore disruption of VE-cadherin junctions sensitises endothelial cells to 
various vascular permeability inducing agents and the formation of 
intercellular VE-cadherin interactions maintain vascular quiescence and act 
as a negative regulator of BRB breakdown (Klaassen et al. 2013). 
 
Adherens junction stability is important for formation and maintenance of 
tight junctions (Tietz & Engelhardt 2015). Disruption of the VE-cadherin and 
N-cadherin junctions leads to the release of β-catenin, activation of the 
Foxo1 transcription factor (Giampietro et al. 2012; Taddei et al. 2008) and 
inhibition of claudin-5 transcription (Taddei et al. 2008). N- and VE-cadherin 
have an additive effect on β-catenin and Foxo1 transcriptional inhibition 
(Giampietro et al. 2012) which means disruption of VE-cadherin junctions 
will exacerbate vessel destabilization due to reduced N-cadherin signalling 
induced by pericyte loss. Inhibition of Foxo1 reduced pericyte loss and 
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endothelial cell apoptosis in diabetic rats (Behl et al. 2009) which indicates 
that this is an important mechanism for diabetes induced vascular 
dysfunction. Since Ang-2 is a transcriptional target of Foxo1 (Kim et al. 
2016), this suggests that vessel destabilization progresses through a 
positive feedback mechanism, in which Ang-2 induced Foxo1 activation is a 
key component. 
 
MMP release and the resulting proteolytic degradation of the ECM is a key 
step in vascular remodeling. Whilst MMP mediated degradation of VE-
cadherin has been shown to contribute to diabetes-induced vascular 
permeability (Navaratna et al. 2007), the role of MMP mediated tight 
junction proteolysis has not been conclusively proven in diabetes. However, 
MMPs have been shown to degrade tight junctions in vitro (Giebel et al. 
2005) and at the blood-brain barrier in vivo (Yang et al. 2007). This may 
mediate the cleavage of the extracellular domains of the tight junction 
complex at the cell membrane and result in tight junction breakdown. 
 
3.3.4.2 increased transcellular permeability 
During diabetes, permeability is increased through the weakening of 
endothelial cell junctions and increased rates of transcellular permeability. 
PLVAP mediates VEGF-induced increases to vascular permeability in the 
retinal (Wisniewska-Kruk et al. 2016) and tumour vasculature (Strickland et 
al. 2005). In addition to its role in transcellular transport, PLVAP is also 
involved in leukocyte transmigration (Keuschnigg et al. 2009), where it has 
been shown to undergo dynamic redistribution following the pattern of 
transmigrating leukocytes within caveolae. Whilst the function of PLVAP in 
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leukocyte transmigration is unknown, it could be involved in the entry of 
leukocytes into caveolae following attachment to the endothelium. Both 
mechanisms of increased permeability may be linked, as leaky endothelial 
cells appear to be both claudin-5 deficient and positive for PLVAP (Zhou et 
al. 2014).  
 
In the normal retina, the level of caveolae is low (Figure 2), which 
suppresses transcellular permeability. The vitamin D transporter, major 
facilitator superfamily domain containing 2A (MFSD2A) is associated with 
the suppression of transcytosis by altering the lipid composition of the 
plasma membrane, leading to a reduction in the level of caveolae (Chow & 
Gu 2017). Although no mechanistic link has been identified, vitamin D 
deficiency is associated with an increased risk of diabetic retinopathy (Luo 
et al. 2017), the absence of MFSD2A or its impaired activity may contribute 
to increased trans-endothelial permeability in diabetic retinopathy. 
 
3.3.4.3 leukocyte recruitment 
Following the activation of pro-inflammatory signalling, initial leukocyte 
recruitment is mediated by expression of P-selectin which allows leukocytes 
to adhere to the vessel wall before binding to intercellular adhesion 
molecule 1 (ICAM-1) (Joussen et al. 2001) and vascular cell adhesion 
molecule 1 (VCAM-1) (Iliaki et al. 2009). Diabetes-induced accumulation of 
AGEs and reactive oxygen species (ROS) have been shown to mediate 
leukocyte adhesion (van der Wijk et al. 2017), due to ICAM-1 and VCAM-1 
upregulation through pro-inflammatory and oxidative stress induced 
signalling pathways (Tang & Kern 2011). Blockade of ICAM-1 (Joussen et al. 
2001) or VCAM-1 (Iliaki et al. 2009) or their respective ligands cluster of 
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differentiation (CD)18 and CD49 prevents leukocyte adhesion and reduces 
inflammation and breakdown of the vascular endothelium. Since infiltrating 
monocytes, unlike microglia, remain in close proximity to the retinal 
vasculature (Stitt et al. 2016), it implies that recruited monocytes mediate 
inflammation around the retinal vasculature rather than at other sites in the 
diabetic retina. 
 
3.3.4.4 endothelial cell apoptosis 
Endothelial cell apoptosis is a key event in the development of diabetic 
retinopathy and has been observed in experimental models of diabetes 
(Joussen et al. 2009). Overexpression of the anti-apoptotic gene B-cell 
lymphoma 2 (Bcl-2) in endothelial cells inhibited microvascular lesions in 
diabetic mice (Kern et al. 2010).  This indicates that endothelial cell 
apoptosis is a key event in the development of microvascular dysfunction, 
at least in rodent models of diabetic retinopathy. In post-mortem tissue 
taken from diabetic patients who had no symptoms of diabetic retinopathy 
(Stitt et al. 2016), there was an increase in the number of apoptotic cells 
(Figure  3 C) in patients with diabetes compared to non-diabetic donors. 
Whilst this did not detect whether apoptosis was occurring in endothelial 
cells specifically, it does indicate that apoptosis in the retina occurs prior to 
the later stages of diabetic retinopathy in humans. 
 
Several mediators of endothelial apoptosis have been identified, including 
ROS (Castilho et al. 2012), inflammatory cytokines (Busik et al. 2008) and 
AGEs (McDonald et al. 2009). VE and N-cadherin activate Akt signalling 
(Giampietro et al. 2012) which promotes endothelial cell survival. Therefore 
 54 
the disruption of VE and N-cadherin junctions attenuates pro-survival 
signalling in endothelial cells and increases their susceptibility to apoptotic 
signals.  
 
Endothelial cell apoptosis leads to the formation of unperfused acellular 
capillaries, which in combination with reduced flow due to impaired glial-
vascular coupling leads to the development of retinal ischemia. This is an 
essential requirement for the generation of pathological neovascularisation 
in PDR.  
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4 Aims of the Thesis 
In humans, progression to PDR is associated with severe vision loss 
resulting from severe vascular changes, but this feature of diabetic 
retinopathy is not observed in animal models of diabetes. Whilst this limits 
the usefulness of animal models for studying this late stage of diabetic 
retinopathy, the lack of therapeutics that prevent the progression of pre-
proliferative diabetic retinopathy presents a major unmet clinical 
requirement. As discussed earlier in this thesis, targeting VEGF has 
potential side effects, which limits the effectiveness of VEGF as a 
therapeutic target, especially as intervention can only take place after some 
disease progression has occurred. Therefore, the primary aim of this thesis 
is to identify potential new ways of treating the early stages of diabetic 
retinopathy by identifying new therapeutic targets, which are more effective 
and with fewer side effects than VEGF. In order to do this, one must 
investigate factors which are altered in diabetes, the effect they have at the 
cell and molecular level, the effect of inhibiting and otherwise altering their 
activity and how these alterations alter the course of the disease. 
 
To study diabetic retinopathy, we have used the streptozotocin induced 
diabetic mouse, a widely used model of type 1 diabetes (Robinson et al. 
2012). Whilst a common criticism of rodent models of diabetes is that they 
fail to model the sight threatening late stages of diabetic retinopathy, this 
feature fits well with the aim of this research. The use of this animal model 
of diabetes will be useful for investigating factors that are altered during the 
early stages of diabetic retinopathy. Linking changes to the transcriptome 
and proteome to specific pathophysiological changes in diabetic retinopathy 
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will be important to understanding how different factors contribute to the 
severity of diabetic retinopathy and whether they have the potential to act 
as therapeutic targets. 
 
In addition to the in vivo work we also use the mouse metatarsal assay 
(Deckers et al. 2001; Song et al. 2015), an ex vivo model of angiogenesis 
to study angiogenesis, and the vasculature in response to diabetic insults 
such as hyperglycaemia and AGE-BSA. Whilst this model is limited in 
comparison to various in vivo systems to investigate the vasculature and 
diabetic retinopathy, it enables a robust and relatively quick method to 
investigate the response of various insults on a model of the vasculature. 
 
Throughout the course of this research, several factors were identified; 
ANGPTL2, ANGPTL6 and LRG1, which were increased in the retinas of 
diabetic mice compared to controls. Therefore, I hypothesised that these 
factors would contribute to the severity of diabetic retinopathy, whilst the 
absence or inhibition of these factors would ameliorate the severity of 
diabetic retinopathy in the experimental models previously described. 
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Chapter 2 Materials 
and Methods  
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1 Molecular and Cell Biology Techniques 
1.1 Metatarsal assay 
The metatarsal assay is an ex-vivo model of angiogenesis in a complex 
multicellular environment which, unlike similar assays such as the aortic 
ring, does not require the addition of exogenous growth factors (Deckers et 
al. 2001; Song et al. 2015). Metatarsal bones were isolated from C57Bl/6 
mice (Harlan) at E16-18. Following decapitation, hindlimbs were removed, 
tissue and skin was stripped from the hindlimb and metatarsal bones were 
dissected and separated. Excess tissue was carefully removed and isolated 
metatarsals were kept in ice cold PBS with 10% foetal bovine serum (FBS)  
until plating. Isolated metatarsals were individually cultured in a 24 well 
tissue culture plate (Thermo Scientific), coated with 0.2% gelatin (Sigma 
Aldrich). Metatarsals were initially grown in 150 µL of α-mem with 10% FBS 
and 100 U/mL of penicillin-streptomycin (Invitrogen). After 3 days the 
medium was replaced with 250 µL of fresh medium with or without 
treatments and refreshed every 48 hours. Metatarsals were cultured for 12 
days, with fresh media being added every 2 days of culture. Metatarsals 
were then either fixed in 4% paraformaldehyde (PFA) for 30 minutes for 
immunofluorescence studies, or RNA was extracted using the RNeasy Micro 
RNA kit (Qiagen), according to the manufacturers instructions. 
 
Angiogenesis was quantified by immunofluorescent labelling of vessel 
sprouts. Metatarsals were blocked with 10% bovine serum albumin (BSA) 
(Signma Aldrich) and 0.1% Triton in phosphate buffered saline (PBS) for 1 
hour at room temperature, followed by incubation with appropriate primary 
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antibodies ((Rat anti-CD31: 1:100 (BD Biosciences), Rabbit anti-neural/glial 
antigen 2 (NG-2): 1:200 (Millipore), Mouse anti-α-smooth muscle actin 
(SMA)-cyanine 3 (Cy3): 1:400 (Sigma Aldrich), Rat anti-PLVAP: 1:100 (BD 
Biosciences)) in 5% BSA with 0.1% Triton in PBS, overnight at 4 oC. This 
was followed by three washes with 0.1% Tween-20 in PBS for 15 minutes. 
All secondary antibodies were purchased from Invitrogen, raised in donkey 
and conjugated to alexa-fluor-488, -555 or -647. Appropriate secondary 
antibodies were incubated at 1:1000 in 5% BSA with 0.1% Triton in PBS for 
2 hours at room temperature. This was followed by three washes with 0.1% 
Tween-20 in PBS for 15 minutes.  
 
To quantify vascular outgrowth in the metatarsal assay, images of CD31 
staining were captured using an Olympus Stereo microscope at 2x 
magnification. Images were analysed using AngioSys 1.0 (Cellworks) to 
quantify the total amount of vessel sprouting and branching. Vessel 
sprouting was defined as the total length of all the vessel sprouts in pixels, 
branching was defined by the number vessel branching points. Within each 
individual experiment the different the level of sprouting and branching was 
normalised to that of the untreated control samples to control for inter-
assay variability.  
 
1.2 Matrigel Assay 
Growth factor reduced Matrigel (BD Biosciences) was defrosted on ice, 
whilst pipette tips and a flat-bottomed 96-well plate were chilled at -20 oC 
for at least 30 minutes. Whilst the 96-well plate and tips were kept on ice, 
50 µL of Matrigel was added to the required number of wells. The plate was 
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then placed in an incubator at 37 oC for 30 minutes to allow the matrigel to 
set. Human umbilical vein endothelial cells (HUVEC) at passages 3-5 were 
used at a concentration of 2x104 cells per well. HUVEC were re-suspended 
in EGM-2 (Lonza) containing either PBS (untreated control), +25 mM 
mannitol (control for osmotic stress) or +25 mM glucose. EGM-2 is a full 
growth media, containing FBS and growth factors, and this media was used 
for this experiment to investigate the impact of hyperglycaemia on EC tube 
formation, which would have been induced by FBS and other growth 
factors, and provides similar conditions to those used in the metatarsal 
assay. The assay was left for 18 hours to allow tube formation to occur, 
following this, the assay imaged by phase contrast microscopy. Tubule 
length and branching were quantified using Angiosys 1.0. 
 
1.3 qPCR 
RNA was extracted from cultured metatarsals or snap frozen mouse retinal 
tissue for quantitative PCR (qPCR) analysis, using the RNeasy Micro RNA kit 
(Qiagen), according to the manufacturers instructions. RNA amount, quality 
and purity were measured spectrophotometerically using a Nanodrop 
(Thermo Scientific). 1 µg of RNA was used to make cDNA using the 
quantitect reverse transcription kit (Qiagen) according to the manufacturers 
instructions. 
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Table 1: Primers used for qPCR analysis 
Power SYBR green master mix (Life Technologies), primers (listed in Table 
1, purchased from Invitrogen) diluted to 5 nM, cDNA and molecular biology 
grade water were combined and 20 µL of the reaction mixture was added 
per well. Each reaction was performed in triplicate and ran on a 
QuantStudio 6 Real Time PCR machine (initial denaturation: 95 oC 10 
minutes, followed by 40 cycles of 15 s at 95 oC and 60 s at 60 oC) 
fluorescence was recorded at each cycle during the annealing step. Relative 
gene expression was calculated by the 2-ΔΔCT method.  
 
1.4 ELISA 
Gene	 Sequence	(5'-3')	
Ang2		
Fwd	 CAGCCACGGTCAACAACTC	
Rev	 CTTCTTTACGGATAGCAACCGAG	
Angptl2		
Fwd	 GAAGCCTGAGAATACCAACCG	
Rev	 CCTTGCTTATAGGTCTCCCAGT	
Angptl6	(exons	1-6)	
Fwd	 CCCGCAGAAGGCAACTAGC	
Rev	 TCTTGGGTGGCTTCTGAGC	
Angptl6	(exons	4-6)	
Fwd	 CCGTGTGGTGTGAACAGCAG	
Rev	 TGAAGAAGTTGACAGAGCCGTC	
Il6	
Fwd	 CTCTGGGAAATCGTGGAAAT	
Rev	 CCAGTTTGGTAGCATCCATC	
Lrg1	
Fwd	 CCATGTCAGTGTGCAGATTC		
Rev	 AAGAGTGAGAGGTGGAAGAG		
Plvap	
Fwd	 GCCAGGTGGTTGGACTATCTG	
Rev	 CTCCATCTCACGTCGCGTA	
Tgfbeta		
Fwd	 TTGCTTCAGCTCCACAGAGA		
Rev	 TGGTTGTAGAGGGCAAGGAC		
Vegf		
Fwd	 GACTTGTGTTGGGAGGAGGA		
Rev	 TCTGGAAGTGAGCCAATGTG		
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Mouse Vegf DuoSet enzyme linked immunosorbent assay (ELISA), Mouse Il-
6 DuoSet ELISA and Mouse Ang-2 quantikine ELISA kits (R&D Systems) 
were used according to the manufacturers instructions. Before analysis, 
samples were centrifuged at 4 oC for 10 minutes to remove particulates and 
the supernatant was diluted 1:3 with 1% BSA (Millipore) in PBS. The plate 
was coated with 0.4 µg/mL of capture antibody overnight, blocked for 1 
hour with 1% BSA in PBS prior to the addition of samples and standards. 
Appropriate biotinylated detection antibodies were used at 100 ng/mL for 2 
hours, followed by addition of streptavidin-HRP diluted 1:40 for 20 minutes. 
Between the additions of each reagent, the plate was washed 3 times with 
0.05% Tween-20 in PBS.  
 
The concentration of the protein interest was determined colourimetrically 
by the addition of 50 µL of H2O2 and tetramethylbenzidine. The 
colourimetric reaction was stopped by addition of 2N H2SO4 and optical 
density was measured at 450 nm and corrected at 570 nm. Protein 
concentrations were determined using regression analysis of a standard 
curve created from the standards. 
 
1.4 SDS PAGE and Western Blot 
4x Laemilli buffer with 100 µM dithiothreitol (DTT) was added to protein 
lysates and boiled at 95 oC for 10 minutes. 10 µg of protein was loaded per 
well in a 4-12% Bis-Tris sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) gel (Invitrogen) and proteins were separated 
by electrophoresis at 150 V for 2 hours. The separated protein was then 
transferred onto a nitrocellulose membrane at 12 V overnight. To check for 
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even transfer of protein onto the membrane, the membrane was incubated 
in 5% ponceu red solution for 5 minutes.  
 
The membrane was then blocked in 5% BSA in tris-buffered saline with 
0.1% Tween-20 (TBST). Membranes were incubated with appropriate 
primary antibodies at 1:1000 (phospho NF-κB p65 or NF-κB p65, both 
antibodies were purchased from Cell Signal Technologies) overnight in 5% 
BSA in 0.1% TBST. Membranes were washed 3 times for 5 minutes in 0.1% 
TBST. Appropriate HRP-conjugated secondary antibodies were added at 
1:1000 in 5% BSA in 0.1% TBST for 2 hours. Membranes were then washed 
for 3 times for 15 minutes in 0.1% TBST. Substrate solution was then to 
each side of the membrane for 1 minute. Excess substrate solution was 
removed and membranes were sealed in plastic film. Chemiluminescence  
was detected by exposing the membrane to an X-ray film (Biocare). The 
amount of protein was quantified by densinometry analysis in ImageJ.  
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2 In vivo Techniques 
2.1 Experimental animals 
C57Bl/6 mice (Harlan) were housed in individually ventilated cages (IVCs) 
with a standard 12-12 hour light/dark cycle with regulated temperature and 
humidity. They were fed a standard laboratory diet and water ad libitum. 
Diabetic mice had their cages changed daily, and fasting blood glucose and 
bodyweight levels were measured every two weeks following the induction 
of diabetes. 
 
Leucine rich glycoprotein 1 (Lrg1) KO mice (Wang et al. 2013) were 
maintained in the same conditions as described above. The Lrg1 KO 
genotype was confirmed by a negative PCR result for the Lrg1 gene and a 
positive PCR result for the LacZ reporter gene. 
 
Genotype	 Sequence	(5'-3')	
Lrg1	
Fwd	 AGGTGAGCGCGCAATGGCTTCA	
Rev	 CAGATCCAACATATCCAGCTGC	
LacZ	
Fwd	 TCCTGGTGGGAGAGGACTC	
Rev	 GTCTGTCCTAGCTTCCTCACTG	
Table 2: primers used for genotyping Lrg1 KO mice 
 
2.2 Streptozotocin induced diabetes 
Male mice were randomly assigned to either control or diabetic groups. 7 
days before the induction of diabetes, mice were fasted for 4 hours. Body 
weight and blood glucose were measured using a Freestyle Optimum blood 
glucose meter (Abbot Diabetes) in order to establish baseline bodyweight 
and blood glucose levels. Diabetes was induced by 5 daily consecutive 
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intraperitoneal (i.p.) injections of freshly prepared streptozotocin (Enzo 
Lifesciences) at 55 mg/kg in pH 4.5 citrate buffer. Control mice received the 
same injections containing citrate buffer alone. 
 
2.3 Fundus Imaging 
The Micron III (Phoenix Research Labs) was used to image the retina using 
brightfield microscopy. Mice were anaesthetised with ketamine at 1.5 mg/kg 
and dormitor at 0.25 mg/kg. Pupils were dilated with 1% tropicamide 
(Chauvins Pharmaceuticals). In addition to brightfield imaging of the 
fundus, the retinal vasculature was imaged using the green filter settings 
following a subcutaneous injection of 100 µL 1% fluorescein isothiocyanate 
(FITC) solution. Images were taken centred on the optic nerve. Immediately 
after image capture, anaesthesia was reversed with anti-sedan at 0.1 
mg/kg. 
 
2.4 Preparation of mouse retinal cryosections 
Freshly enucleated eyes were fixed in 2% PFA in 2x PBS for 15 minutes. 
Following this excess tissue was trimmed from the posterior part of the eye 
and an incision was made anterior to the ora serata. The anterior part of 
the eye was cut away and removed along with the lens. The remaining 
eyecup was post-fixed in 4% PFA for 1 hour then added to a 30% sucrose 
solution overnight. The next day the eyecup was embedded in optimal 
cutting temperature compound (OCT) and rapidly frozen in dry ice cooled 
acetone before being stored at -80 oC. 10 µM sections were cut in a cryostat 
at -20 oC and captured on superfrost adhesion slides (VWR). Slides were 
allowed to dry at room temperature before being stored at -80 oC. 
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Sections were blocked for 1 hour at room temperature in 1% BSA with 
0.5% Triton in PBS, followed by incubation with appropriate primary 
antibodies (Rabbit anti-ionised calcium-binding adapter molecule 1 (Iba1); 
1:200, Rabbit anti-NF-κB; 1:100, Donkey anti-mouse IgG-488, 1:1000) in 
fresh blocking buffer at 4 oC overnight. Sections were washed three times 
with 0.1% Tween-20 in PBS for 5 minutes. All secondary antibodies were 
purchased from Invitrogen, raised in donkey and conjugated to alexa-fluor-
488, -555 or -647. Appropriate secondary antibodies diluted 1:1000 in 
blocking buffer. Sections were then washed twice in 0.1% Tween-20 for 15 
minutes before being counterstained with 4',6-diamidino-2-phenylindole 
(DAPI) at 1:1000 in PBS for 10 minutes. Sections were then washed twice 
in PBS before being mounted under coverslips with DAKO fluorescent 
mounting medium (DAKO). 
 
2.5 Preparation of mouse retinal flatmounts 
Freshly enucleated eyes were fixed in 4% PFA for 1 hour. An incision was 
posterior to the ora serata, before being cut laterally with dissecting 
scissors to remove the anterior part of the eye. The optic nerve was then 
cut and the neurosensory retina was carefully separated from the RPE-
choroid layer. Four radial incisions were made at 90o to each other towards 
the centre to allow the retina to lay flat. The retina was then post-fixed in 
ice-cold methanol for 15 minutes. Retinas were either stored at -20 oC in 
methanol or the immunostaining protocol was started. 
 
Prior to immunofluorescence staining, retinas were rehydrated with five 
washes in PBS. Retinas were then blocked for 1 hour at room temperature 
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in 0.5% BSA, 3% Triton and 1% Tween-20 in PBS. After blocking, retinas 
were incubated with the appropriate primary antibodies overnight at 4 oC in 
the blocking solution with gentle agitation. Retinas were then washed with 
fresh blocking solution three times for 15 minutes. Appropriate secondary 
antibodies were diluted 1:1000 in blocking buffer and added for 2 hours at 
room temperature. The retinas were then washed with fresh block three 
times for 30 minutes before being counterstained with DAPI for 10 minutes 
in PBS. After two further washes in PBS, retinas were mounted with DAKO 
fluorescent mounting medium (DAKO). 
 
2.6 Intravenous administration of FITC-dextran 
Mice were warmed in a 37 oC heat box to induce vasodilation before being 
restrained. 100 µL of 5 mg/mL of 40 kDa FITC-dextran (Invitrogen) was 
injected into the tail vein using a 30 G needle. The dextran was allowed to 
circulate for 1 hour before the mice were culled by cervical dislocation and 
tissue was extracted. 
 
3 Statistics 
Students t-test was used to analyse the difference between samples in all 
data. Welch’s t-test was used to analyse the difference in samples from in 
vivo work due to the unequal variance in the two groups, due to a 
statistically significant difference following an F-test. All data are expressed 
as the mean with error bars as the standard error of the mean (SEM). 
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Chapter 3 Results  
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The link between hyperglycaemia and inflammatory-mediated vascular 
dysfunction in diabetes has been extensively studied in vivo (Bakker et al. 
2009; Kolluru et al. 2012). Various factors have limited the effectiveness of 
equivalent in vitro studies, such as; differences between macrovascular and 
microvascular endothelial cells (Duffy et al. 2006), the lack of appropriate 
controls for osmotic stress (Yin et al. 2012; J. Zhao et al. 2015), and the 
relatively short-term nature of in vitro studies. Despite this, hyperglycaemia 
has been demonstrated to have some direct effect on endothelial cells in 
vitro, such as endothelial senescence (Maeda et al. 2015) and apoptosis 
(Sheu et al. 2005). 
 
Various in vitro studies indicate that exposure of perivascular cells to high 
glucose alters the behaviour of endothelial cells via paracrine mediators 
(Kim 2002; Busik et al. 2008; Pfister et al. 2008; Yun et al. 2017). This 
indicates that high glucose-induced dysfunction in perivascular cells has an 
important role to play in diabetes-associated vascular dysfunction. 
Therefore, whilst treating endothelial cells with high glucose allows us to 
perform relatively simple studies on the effects of hyperglycaemia, utilising 
more complex, multicellular models offers greater insight into diabetes-
induced changes to the vasculature. It is important to note that these in 
vitro models are still unable to fully recapitulate the diabetes-induced 
changes to the vasculature that occur in vivo. Since vascular changes in 
diabetic retinopathy occur in the context of the systemic vasculature, 
diabetes induced changes may in other organs may indirectly lead to 
changes in the retinal vasculature such as through circulating immune cells 
and endocrine signalling. Hence, the requirement for animal models of 
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diabetes, which will be discussed in the next chapter. An overview of the 
different models used in this thesis (Figure 8). 
 
Figure 8: Schematic of the different experimental models used in 
this thesis. The three models, in order of increasing complexity are 
cultured endothelial cells, the mouse embryonic metatarsal assay and the 
streptozotocin (Stz) induced diabetic mouse, an in vivo model of type 1 
diabetes.  
 
1 Hyperglycaemia and angiogenesis in vitro 
To investigate the role of hyperglycaemia on endothelial cell proliferation 
and tube formation, the Matrigel assay was used. HUVEC were seeded onto 
Matrigel-coated wells of a 96-well plate in culture media containing PBS, 25 
mM mannitol or 25 mM glucose. Glucose concentrations ranging between 20 
and 30 mM have been widely used to replicate hyperglycaemia in vitro 
(Duffy et al. 2006; Sheu et al. 2005; Suarez et al. 2015; X.-Y. Zhao et al. 
2015). Additionally, this concentration matches the blood glucose level 
frequently observed in mouse models of diabetes (Figure 28). The assay 
 71 
was performed for 18 hours overnight before tube formation was imaged 
and quantified. Compared to PBS (Figure 9 A) and mannitol (Figure 9 B), 
tube formation was significantly (p<0.001) reduced by 30% in the high 
glucose treatment (Figure 9 C), although there was no quantitative change 
in the amount of branching (Figure 9 E). 
 
 
Figure 9: High glucose reduces tube formation in the Matrigel assay. 
Representative images taken by phase contrast of the HUVEC Matrigel 
assay with PBS (A), 25 mM mannitol (B) or 25 mM glucose (C). 
Quantification of sprouting length showed a reduction in glucose-treated 
samples compared to PBS or mannitol-treated assays (D). No change in 
branching was observed between treatments (E). Data representative of 3 
independent experiments with at least 6 wells used for each treatment in 
each experiment. Stastical analysis performed using studnets T-test. *** = 
p<0.001. Scale bar = 500 µm. 
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Having shown that tube formation in the Matrigel assay was impaired in 
hyperglycaemic conditions, the effects of hyperglycaemia on angiogenesis in 
the metatarsal assay were investigated. The metatarsal assay is a 
multicellular angiogenesis involving endothelial cells with associated mural 
cells such as pericytes, fibroblasts and macrophages, and doesn’t require 
the addition of exogenous growth factors (Deckers et al. 2001; Song et al. 
2015). This permits the investigation of effects of hyperglycaemia on 
angiogenesis in a multicellular environment. To our knowledge, this is the 
first time the effects of hyperglycaemia have been investigated in a 
multicellular model of angiogenesis. 
 
Three days after dissecting and plating the metatarsals, the cultures had 
attached and established with vessel sprouts starting to form. The media 
was changed and replaced with treatments of either PBS, 25 mM mannitol 
(the osmotic control) or 25 mM glucose. Media containing the relevant 
treatments was changed four times every two days. Compared to PBS and 
mannitol treatments (Figure 10 A-B), metatarsals cultured in media with 25 
mM glucose (Figure 10 C) had a 25% reduction (p<0.05) in vessel 
sprouting and branching (Figure 10 D-E). This indicates that elevated 
glucose levels impair new vessel growth, as observed in the Matrigel assay 
(Figure 9) and that osmotic stress is unlikely to have played a role in 
reducing the total level of sprouting. 
 
Taken together, Figure 9 and Figure 10 show that hyperglycaemia impairs 
the formation of vessel sprouting, and that these relatively simple models 
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may re-capitulate aspects of diabetes-induced vascular dysfunction which 
result from elevated blood glucose. 
 
Figure 10: High glucose reduces vessel growth and branching in the 
metatarsal assay. Metatarsals were cultured for 10 days with PBS, 25 mM 
mannitol and 25 mM glucose, and then fixed and stained for CD31 to label 
endothelial cells (A-C). Quantitative analysis of CD31 staining to measure 
vessel sprouting (D) and vessel branching (E) showed that high glucose 
reduces vessel sprouting compared to PBS or mannitol controls. Data from 
4 independent experiments with at least 12 individual bones used for each 
treatment in each experiment. Statistical analysis was performed using 
students T-test. * = p<0.05. Scale bar = 500 µm. 
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Altered expression of pro-angiogenic factors such as Vegf and Ang2 has 
been shown to promote vascular dysfunction in diabetic retinopathy (Ishida 
et al. 2003; Yun et al. 2016). As expression of these and other angiogenic 
factors may be altered by hyperglycaemia, I next investigated whether 
reduced vessel sprouting in the metatarsal assay (Figure 11) was 
accompanied by changes in growth factor expression. Whilst a more 
exhaustive approach would be to perform microarray to investigate changes 
to the transcriptome and proteome in response to high glucose, the costs 
associated with this technique meant that a candidate gene based approach 
was utilised instead. 
 
Because Vegf plays an important role in angiogenesis, both gene expression 
and protein secretion were examined (Figure 11 A-B). qPCR analysis 
showed that there was no significant difference in the level of mRNA 
expression in high glucose conditions compared to controls (Figure 11 A). In 
contrast, the level of Vegf detected in the conditioned media was reduced in 
high glucose treated metatarsals compared to controls (Figure 11 B), 
consistent with the data in Figure 9 and Figure 10. Since Ang-2 also plays a 
key role in promoting angiogenesis (Felcht et al. 2012), we measured its 
mRNA and protein levels. Similar to Vegf, no significant change in the level 
of Ang2 mRNA was detected (Figure 11 C), however there was a small, 
~20% but non-significant reduction in the level of Ang-2 in the conditioned 
media. Lrg1 has been previously been shown to be upregulated in the 
vitreous of patients with PDR, and promotes angiogenesis and vascular 
leakage by modifying Tgf-β signalling (Wang et al. 2013). To investigate 
whether high glucose had any effect on Lrg1 and Tgf-β, qPCR analysis of 
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both genes was performed. No statistically significant changes in gene 
expression were observed (Figure 11 E-F). Analysis of these angiogenic 
factors suggests a trend towards a decrease in expression in the presence 
of high glucose, although this was not statistically significant. However, this 
trend does fit in with the previously described trend for a reduction in 
angiogenesis in response to high glucose treatment. The lack of statistical 
significance in the findings in Figure 11 indicate that the response to high 
glucose is relatively minor and that further work to optimise this assay in 
order to detect an enhanced response may reveal more robust changes in 
gene expression alongside other findings.  
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Figure 11: High glucose reduces Vegf secretion in the metatarsal 
assay, but does not alter the expression of other growth factors. 
Metatarsals were cultured with PBS, 25 mM mannitol or 25 mM glucose as 
described in Figure 9. RNA was extracted and prepared for qPCR analysis. 
ELISAs were performed on conditioned media taken the same day as the 
RNA extraction. Whilst Vegf expression was not altered (A), there was a 
small but statistically significant reduction in secreted Vegf in the 
conditioned media (B). Ang-2 expression was not altered (C), but there was 
a slight but non-significant reduction in secreted Ang-2 in the conditioned 
media (D). There were no changes to Tgfbeta (E) or Lrg1 (F) expression. 
Data are from 3 independent experiments with at least 12 individual bones 
per experiment. Statistical analysis was performed using students T-test. * 
= p<0.05. 
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Reduced pericyte coverage is known to be associated with vascular 
dysfunction in diabetic retinopathy (Ogura et al. 2017). High glucose has 
been shown to affect pericytes in vitro, by reducing contractility and 
proliferation, and increasing apoptosis (Beltramo et al. 2006; Suarez et al. 
2015). Therefore, we were interested in seeing whether high glucose would 
alter the biology of pericytes and their association with endothelial cells in 
the metatarsal assay. Selecting appropriate markers for pericytes is 
challenging and can be contentious, as there is no universal marker for all 
pericytes, the expression of different markers changes as pericytes migrate 
and attach to the endothelium (Armulik et al. 2011), additionally the 
reliability of some commercially available antibodies cannot be guaranteed. 
Two of the most widely used markers for pericytes are α-SMA and NG-2. To 
determine which was most appropriate in the metatarsal assay, the staining 
of both markers was compared by immunofluorescence (Figure 12 A-C). 
NG2 (Figure 12 A) appeared to be a better marker than α-SMA (Figure 9 B) 
as its expression was restricted to perivascular cells (Figure 12 A-C), whilst 
α-SMA also appeared to be expressed in other cell types.  
 
To assess the ratio of pericytes to endothelial cells, metatarsals were 
treated with PBS (Figure 12 D), 25 mM mannitol (Figure 9 E) or 25 mM 
glucose (Figure 12 F) as previously described. After 10 days in culture, the 
metatarsals were fixed and stained for CD31 and NG2, and the ratio of NG2 
to CD31 staining was quantified (Figure 12 G). No change in the ratio of 
NG2 to CD31 was detected which implies that there were no alterations to 
pericyte staining upon high glucose treatment. 
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Figure 12: High glucose does not alter the pericyte-endothelial cell 
ratio in the metatarsal assay. Microscopy was used to identify a suitable 
pericyte marker to quantify pericyte coverage in the metatarsal assay (A-
C). Staining for CD31 in combination with NG2 (A) and α-SMA (B) showed 
that NG2 is a more appropriate marker of pericytes in this assay. Whilst 
NG2 and α-SMA showed some co-localisation (C), α-SMA also stained cells 
that were not directly associated with endothelial cells (white arrowheads). 
Representative low power images of CD31 and NG2 staining in metatarsals 
treated with PBS (D), 25 mM mannitol (D) or 25 mM glucose (E) as 
previously described in Figure 10. The image area containing the bone was 
masked, and the ratio of NG2 to CD31 staining was quantified (G) indicating 
there is no change to pericyte staining in metatarsals cultured under high 
glucose conditions. Data representative of two independent experiments. 
Scale bar = 10 µm (A-C), 500 µM (D-F).   
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2 AGE-BSA and angiogenesis in vitro 
Supplementing growth media with glucose is a simple strategy to 
investigate the effects of hyperglycaemia in vitro, however, it fails to 
replicate the complex nature of the diabetic environment in vivo. An 
increase in advanced glycation end products (AGEs), such as circulating 
glycated haemoglobin, have been linked to the incidence and severity of 
microvascular complications of diabetes such as DR (Sabanayagam et al. 
2009). AGE measurements therefore provide a better indicator of glucose 
control and diabetes severity than fasted blood glucose measurements. 
Additionally, AGE formation has also been linked to the pathophysiology of 
diabetic retinopathy in mouse models of experimental diabetes (Stitt 2010). 
AGE induces inflammation primarily through activation of its receptor, 
RAGE, and its downstream pro-inflammatory signalling pathways, as well as 
through other non-RAGE signalling pathways (Stirban et al. 2014). 
Therefore, in addition to acting as a biomarker for diabetes severity, 
circulating glycated proteins may contribute to diabetes-induced vascular 
dysfunction. RAGE blockade, with a soluble RAGE isoform improved wound 
healing (Goova et al. 2001), and treatment with a RAGE-IgG fusion protein 
reduced the severity of diabetic retinopathy (Li et al. 2011), both in diabetic 
mice. These studies therefore indicate a direct role for AGE/RAGE signalling 
in mediating the vascular complications of diabetes. 
 
Albumin is an abundant circulating protein, and can undergo modification 
with AGEs in vivo so this constitutes a suitable reagent for the in vitro 
delivery of AGEs. Therefore, in an attempt to better model the effects of 
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diabetes on the vasculature, metatarsals were cultured with exogenously 
added AGE-BSA to investigate the effects of AGE in this explant model. 
 
Untreated (Figure 13 A), 100 µg/mL BSA (Figure 13 B) or 100 µg/mL AGE-
BSA (Figure 13 C) treatments were added on the third day in culture and 
replaced every two days. Quantification of vessel sprouting (Figure 13 D) 
and branching (Figure 13 E) showed that AGE-BSA (Figure 13 C) lead to a 
two-fold increase (p<0.05) in sprouting of new vessels compared to 
untreated and BSA treated metatarsals (Figure 13 A-B), in contrast to our 
previous findings with high glucose treatments (Figure 10). This could be 
explained by the different mechanisms of action of high glucose and AGE-
BSA on the vasculature when they are given separately. In an in vivo model 
of diabetes both hyperglycaemia, AGE-BSA and other factors would no 
doubt act in concert to provide the diabetic phenotype. 
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Figure 13: AGE-BSA increases vessel growth and branching in the 
metatarsal assay. Representative images of metatarsals cultured as 
previously described with growth media supplemented with; PBS (A), 100 
µg/mL BSA (B) or 100 µg/mL AGE-BSA (C). Quantitative image analysis of 
CD31 staining was performed to measure vessel sprouting (D) and 
branching (E) which revealed that 100 µg/mL AGE-BSA increased both 
vessel sprouting and branching. Data are from 3 independent experiments 
with at least 12 bones used per treatment in each experiment. Statistical 
analysis was performed using students T-test. * = p<0.05. Scale bar = 500 
µm. 
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AGE-BSA induced a two-fold increase in vessel sprouting (Figure 13), and 
AGE-BSA has been previously shown to alter gene expression in vitro 
(Wang et al. 2011), including that of VEGF (Yamagishi et al. 1997), 
probably through NF-κB dependent signalling (Hoesel & Schmid 2013). I 
therefore decided to investigate whether AGE-BSA treatment upregulated 
Vegf and the expression of other angiogenic genes in the metatarsal assay. 
After the final treatment, the RNA was extracted and prepared for qPCR 
analysis. AGE-BSA treatment led to a three-fold (p>0.05) increase in both 
Vegf mRNA (Figure 14 A) and protein (Figure 14 B) levels, which is in 
agreement with previous in vitro studies showing that AGE-BSA induces 
VEGF production (Yamagishi et al. 1997).  
 
As Lrg1 and Tgf-β work together to induce angiogenesis, the expression of 
both genes was analysed by qPCR to determine whether their expression 
was induced by AGE-BSA treatment. Whilst Tgfbeta (Figure 14 D) and Lrg1 
(Figure 14 C) expression appeared to be increased two-fold and four-fold 
respectively in response to AGE-BSA, only the increase in Lrg1 was 
statistically significant. Since Il-6 has been shown to be increased in 
diabetic retinopathy (Chen et al. 2016) and pathological angiogenesis 
(Gopinathan et al. 2015), Il-6 mRNA (Figure 14 E) and protein (Figure 14 F) 
were also measured. Il6 mRNA was markedly upregulated with a 60-fold 
increase in response to AGE-BSA treatment, in contrast to its low level of 
expression under control conditions. A similar pattern for the 60-fold 
increase in Il-6 protein levels was also observed (Figure 14 F), however, 
since the data are from only two independent experiments statistical 
analysis was not performed.  
 83 
 
Figure 14: AGE-BSA increases the production of pro-angiogenic and 
pro-inflammatory growth factors in the metatarsal assay. Metatarsals 
were cultured as described in Figure 10. RNA was extracted and prepared 
for qPCR analysis, gene expression was normalised to the endogenous 
control, Hprt. ELISAs were performed on conditioned media taken the same 
day as the RNA extraction. Vegf mRNA (A) and protein (B) levels were 
increased following treatment with 100 µg/mL AGE-BSA compared to 
control treatments. Lrg1 (C) and Tgfbeta (D) expression appeared to be 
increased in response to AGE-BSA treatment, however, this increase was 
not statistically significant. In contrast, Il6 expression was strongly induced 
in response to AGE-BSA treatment (E). A similarly strong increase in 
secreted Il-6 was also detected but statistical analysis was not performed as 
there were only two experimental replicates. Data are from 3 independent 
experiments, apart from F, which is the result of 2 independent 
experiments. Statistical analysis was performed using students T-test. * = 
p<0.05.  
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Having shown a 60-fold increase in Il-6 mRNA and protein in response to 
AGE-BSA treatment (Figure 14 E-F), which in agreement with (Figure 13) 
implies that AGE-BSA exerts a pro-angiogenic effect in the metatarsal 
assay. I was interested in what effect the increase in Il-6 would have on the 
metatarsal assay. The janus kinase/signal transducer and activator of 
transcription (JAK/STAT) signalling pathway is activated by IL-6, which 
culminates in phosphorylation of the STAT3 transcription factor, and has a 
well-established role in inflammation and angiogenesis (Scheller et al. 
2011; Oh et al. 2012; Yun et al. 2017). In order to determine whether the 
increase in Il-6 also increased the level of JAK/STAT signalling, cultured 
metatarsals were treated with 100 µg/mL BSA or 100 µg/mL AGE-BSA and 
stained for pSTAT3 (Figure 15). 
 
Although not statistically significant, staining for pSTAT3 was increased by 
10% in AGE-BSA treated metatarsals (Figure 15 A-C), compared to control 
metatarsals, which were treated with BSA alone (Figure 15 D-F). 
Quantification of pSTAT3 staining confirmed a trend towards an increase in 
pSTAT3 staining in AGE-BSA treated samples (Figure 15 E) However, 
caution must be used when interpreting this finding, as the pSTAT3 staining 
was not specific to the nucleus and this experiment was only performed 
once with only three samples per treatment. Nevertheless, the increase in 
STAT3 phosphorylation demonstrated here suggests that one mechanism 
through which AGE-BSA increases angiogenesis may be through Il-6 
dependent activation of STAT3, mediating increased angiogenesis in a pro-
inflammatory dependent context. 
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Figure 12: Staining for pSTAT3 is increased in AGE-BSA treated 
metatarsals. Metatarsals were cultured as previously described with either 
100 µg/mL BSA or 100 µg/mL AGE-BSA. Samples were stained for CD31 to 
label endothelial cells, and a phospho-specific antibody to STAT3 (pSTAT3) 
to examine STAT3 phosphorylation. The level of pSTAT3 appears to be 
increased in AGE-BSA treated (A-C) over BSA treated (D-F) metatarsals. 
pSTAT3 staining was quantified and normalised to CD31 staining (G) which 
revealed a trend for increased pSTAT3 staining in AGE-BSA treated 
samples. Data from 3 bones per treatment and representative of one 
independent experiment. Scale bar = 100 µm. 
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Plasmalemma vesicle associated protein (Plvap) is an endothelial cell-
specific marker of increased vascular permeability and is expressed at 
fenestrae and caveolae. Whilst these organelles are unlikely to have a 
functional role in the vascular network produced in the metatarsal assay, 
both play an important role in mediating vascular permeability amongst 
other functions in vivo. Additionally, elevated levels of Plvap are associated 
with disease-induced vascular abnormalities (Guo et al. 2016), and have 
been reported to be associated with vascular leakage in the Akimba mouse 
model of diabetes (Wisniewska-Kruk et al. 2014). Plvap upregulation is also 
induced by Vegf (Wisniewska-Kruk et al. 2016). Considering the previous 
data showing AGE-BSA induced angiogenesis (Figure 13) and Vegf 
upregulation (Figure 14), I next asked whether Plvap is also up-regulated in 
response to AGE-BSA treatment. 
 
To determine whether AGE-BSA altered the level of Plvap, qPCR and IF 
analysis were performed on cultured metatarsals. Following AGE-BSA or 
BSA (Figure 16 A-F) treatment, the intensity of Plvap staining was 
quantified and normalised to Collagen IV staining (Figure 16 G). However, 
only a very slight increase in Plvap staining was detected suggesting that 
AGE-BSA has little impact on Plvap expression in the metatarsal assay. This 
observation was confirmed by qPCR analysis of Plvap mRNA (Figure 16 H) 
where no significant change in Plvap expression was observed. 
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Figure 16: Plvap is not altered by AGE-BSA treatment in the 
metatarsal assay. Metatarsals were cultured with 100 µg/mL AGE-BSA (A-
C) or 100 µg/mL BSA (D-F) as previously described. Plvap staining was 
quantified and normalised to collagen IV staining (G) and there was only a 
slight increase in Plvap staining intensity in AGE-BSA treated metatarsals. 
qPCR analysis of Plvap mRNA showed there was no alteration in the level of 
gene expression (H). Scale bar = 100 µm. Data representative of two 
independent experiments. 
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After completing the experiments, and because of insufficiently detailed 
information from the manufacturer (Millipore) about the purity of the AGE-
BSA, I performed an endotoxin test on the material. This is because 
endotoxin has previously been shown to exert a pro-angiogenic effect on 
endothelial cells and also activates inflammatory signalling pathways, which 
are downstream of RAGE (Pollet et al. 2003).  
 
Although testing revealed the presence of endotoxin, it is not clear whether 
contamination occurred during the course of the study, or, if earlier batches 
of this reagent were affected, and time did not permit an investigation of 
this issue. Testing did reveal that the endotoxin concentration when the 
AGE-BSA was diluted to its working concentration of 100 µg/mL would have 
been ~ 10 pg/mL. Other studies have shown endotoxin to induce 
angiogenesis at concentrations >2 ng/mL in vivo (Mattsby-Baltzer et al. 
1994) and >100 ng/mL in vitro (Pollet et al. 2003; Li et al. 2017). Other 
reports have shown AGE-BSA to induce VEGF expression (Mamputu & 
Renier 2004), in which the authors explicitly state in the manuscript that 
endotoxin testing was performed on their AGE-BSA preparations. To 
determine what concentration of endotoxin affected angiogenesis in the 
metatarsal assay exogenous endotoxin could be titrated in to determine the 
minimum concentration of endotoxin required to induced angiogenesis in 
this model. Repeat studies using AGE-BSA confirmed to be endotoxin-free 
would need to be performed before drawing too many conclusions from 
these data. 
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Chapter 4 Results  
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Whilst in vitro and ex vivo models are useful tools for vascular biology 
research, they are not able to replicate the complex nature of the 
vasculature in living tissue. Additionally, the unique biology and complex 
neurovascular interactions in the retina differ substantially from what can 
be replicated in vitro. Therefore, to gain an understanding of a complex 
vascular complication of diabetes such as diabetic retinopathy, animal 
models of diabetes are essential. 
 
The streptozotocin-induced mouse model of diabetes is widely used to study 
diabetes in vivo, with a Pubmed search for ‘streptozotocin mice’ returning 
over 6,000 results. Streptozotocin enters β-cells through glucose 
transporter 2 (Glut-2) and exerts its cytotoxic effect through DNA damage-
mediated activation of the Poly-ADP ribose polymerase (PARP) apoptosis 
pathway (Chaudhry et al. 2013). β-cells are responsible for insulin 
production, and their destruction leads to hyperglycaemia due to a lack of 
insulin production. Other widely used models of diabetes to study diabetic 
retinopathy include; Ins2Akita and Akimba mice as well the streptozotocin 
induced diabetic rat. The main advantage of these other models is that they 
have been reported to recreate the severity and the range of features of 
human diabetic retinopathy in a shorter time frame. However, the initial 
costs to acquire these models and the time and the animal usage required 
to cross these animals onto other transgenic mouse lines, and in the case 
with rats increased maintenance costs, means that the streptozotocin 
mouse model has certain practical advantages.  
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1 The streptozotocin-induced diabetic mouse retina 
Therefore, the aim of work in this chapter was to examine the 
streptozotocin-induced diabetic mouse for signs of changes associated with 
diabetic retinopathy. One of the main aims of this study was to identify 
changes that occur prior to the onset of more overt pathology, and to try 
and identify novel targets for therapeutic intervention. There is at present a 
largely unmet clinical need for therapeutics to manage the early stages of 
DR, with the anti-VEGF Aflibercept being the frontline treatment, and 
effective in <50% of patients. Diabetes was induced with 5 daily i.p. 
injections of streptozotocin, with age-matched controls receiving i.p. 
injections of vehicle. Induction of diabetes was confirmed by at least 3 
consecutive fasted blood glucose measurements >20 mM. 
 
Fundus photography and fluorescein angiography are widely used in the 
clinic to non-invasively monitor diabetic patients for signs of retinopathy 
(Stitt et al. 2015) (Figure 4). The retinas of control and diabetic mice were 
initially examined by fundus imaging and fluorescein angiography (Figure 
17) to assess any changes to the retina two months after diabetes 
induction. Unexpectedly, fluorescein angiography did not reveal any 
evidence of vascular leakage in diabetic compared to control (Figure 17 C-
D) mice. However, analysis by fundus imaging suggested that there were 
some changes, with white spots observed in diabetic retinas (Figure 17 B, 
white arrowheads), which were absent in control (Figure 17 A) mice. Whilst 
there is no evidence of a severe phenotype in the retina from this analysis, 
this could indicate the presence of inflammatory infiltrates into the retina. 
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Figure 17: Fundus imaging and fluorescein angiography of diabetic 
and control mouse retinas. Fundus imaging was performed two months 
following diabetes induction. Brightfield imaging in control (A) and diabetic 
(B) retinas revealed some minor changes to the retina in diabetic mice 
(white arrowheads) which may indicate areas of inflammation. There was 
no evidence of vascular leakage in control (C) or diabetic (D) retinas 
analysed by fluorescein angiography imaged 10 minutes after subcutaneous 
injection of fluorescein. Images representative of 6 mice per condition. 
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Glial fibrillary acidic protein (GFAP) is a specialised intermediate filament 
protein expressed in astrocytes and Müller cells in the retina. GFAP 
expression is altered in diabetes and is a well-characterised sign of retinal 
stress (Feit-Leichman et al. 2005). GFAP expression in the Müller cell is a 
sign of gliosis, which contributes, to inflammation and vascular leakage 
(Bringmann & Wiedemann 2012). To investigate changes to the macroglia 
in the diabetic retina, GFAP expression was analysed in retinal cryosections 
two months after the induction of diabetes. In control (Figure 18 A-C) mice, 
GFAP expression was strictly limited to the ganglion cell layer (GCL). 
However, in diabetic mice (Figure 18 D-F), there was some indication of 
GFAP expression protruding deeper into the retina in what may be a 
terminal process of the Müller cell (Figure 18 D-F, white arrowhead). This 
suggests some evidence of mild stress in the retina. Since this is a minor 
phenotype which in itself is not indicative of functional change in the 
diabetic retina quantitative image analysis was not performed.  
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Figure 18: GFAP expression in control and diabetic mouse retinal 
cryosections. 12 µm cryosections were cut from OCT embedded mouse 
eyes and stained for GFAP to examine changes to the glial cells of the retina 
in diabetic mice two months after the induction of diabetes. In control mice 
(A-C) GFAP staining was strictly limited to the ganglion cell layer. In 
diabetic mice (D-F) some GFAP staining was seen in the inner plexiform 
layer (white arrowhead), but did not protrude deeper into the retina. GCL = 
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. 
Images representative of sections taken from 3 different control and 
diabetic mice. Scale bar = 20 µm. 
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Microglia are a tissue resident population of macrophages, which normally 
reside in the inner plexiform layer (located between the GCL and INL). 
During retinal stress or inflammation they adopt an amoeboid and 
migratory phenotype and enter the ganglion cell layer and inner nuclear 
layer (Tang & Kern 2011). Since microglia are an important source of 
inflammatory mediators and play a role in the death of retinal neurons 
(Krady et al. 2005), microglial activation is a key step in the progression of 
diabetic retinopathy.  
 
Mouse retinal cryosections were stained for Iba1 to investigate changes to 
the distribution and morphology of immune cells in the retina. Iba1 is a 
marker expressed in both the resident microglia of the retina and in 
infiltrating macrophages from the circulation in response to pro-
inflammatory signalling. It is not possible to differentiate between resident 
microglia and recruited monocytes by IF (Caicedo et al. 2005), so Iba1 
staining will label both tissue resident and recruited macrophages. Iba1+ 
cells appeared to adopt an amoeboid phenotype and to have migrated into 
the GCL and the INL in sections from diabetic mice (Figure 19 D-F, white 
arrow heads), with neither feature apparent in control mice (Figure 19 A-C) 
Quantitative image analysis revealed that the number of infiltrating immune 
cells was significantly (p>0.01) increased in diabetic retinas compared to 
controls.  
  
 96 
 
Figure 19: Iba1 staining in control and diabetic mouse retinal 
cryosections. 12 µm cryosections were stained for Iba1 to investigate 
changes to resident and infiltrating immune cells two months following the 
induction of diabetes. In control (A-C) retinas, a low level of Iba1 staining is 
found throughout the inner retina. In (A, C) there appears to be some non-
specific staining in the ganglion cell layer. In diabetic (D-F) mice some 
microglia have undergone a conformational change and migrated into the 
ganglion cell layer and inner nuclear layer, as shown by white arrowheads 
(F). The number of Iba1+ immune cells infiltrating into the GCL and INL 
was quantified after masking the identify of each image (G). Images 
representative of sections from 3 control and 3 diabetic mice. GCL = 
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer. 
Scale bar = 20 µm. ** = p<0.01. 
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The development of oxidative stress in the diabetic retina is a key stage in 
the pathophysiology of diabetic retinopathy (Kowluru & Chan 2007), where 
it is associated with activation of pro-inflammatory and pro-angiogenic 
signalling pathways (Kim et al. 2013; West et al. 2010). 4-Hydroxynonenal 
(4-HNE), a marker of lipid peroxidation, is elevated in conditions of 
oxidative stress. Hence making it a good marker for oxidative stress-
induced cellular changes.  
 
To determine whether oxidative stress was increased in the diabetic retina, 
cryosections were stained for 4-HNE and analysed by IF (Figure 20). 4-HNE 
staining appeared to be increased in the diabetic retina (Figure 20 D-F), 
compared to the control retina (Figure 20 A-C) with the greatest increase in 
4-HNE staining in the photoreceptors. Quantitative image analysis revealed 
a 3-fold increase in 4-HNE staining in diabetic retinas compared to controls 
(Figure 20 G). This is consistent with a previous publication which showed 
that photoreceptors are a major contributor to oxidative stress in the 
diabetic retina (Du et al. 2013), and provides further evidence of early 
pathological changes in the diabetic retina. 
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Figure 20: 4-HNE staining in the control and diabetic mouse retina. 
12 µm cryosections were stained for 4-HNE to examine oxidative stress-
induced changes to the retina in control (A-C) and diabetic (D-F) mice two 
months after the induction of diabetes. The amount of 4-HNE staining 
appeared to be increased in the photoreceptors (located below the ONL) in 
sections from diabetic retinas, also indicated by quantitative image analysis 
(G), which revealed a statistically significant increase in 4-HNE staining in 
diabetic retinas. Images representative of sections from 3 control and 3 
diabetic mice. GCL = ganglion cell layer, INL = inner nuclear layer, ONL = 
outer nuclear layer.  Scale bar = 20 µm. ** = p<0.01. 
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NF-κB is a transcription factor which induces the transcription of various 
pro-inflammatory cytokines such as Tnfα, Il1beta and Il6 in response to 
pro-inflammatory signalling (Hoesel & Schmid 2013). It is known to be 
involved in diabetic retinopathy, where it’s induced by Vegf and other 
cytokines (Barlovic et al. 2011; Bai et al. 2009; Tang & Kern 2011). The 
levels of the phosphorylated p65 subunit of NF-κB were measured by IHC 
and western blot to examine the inflammatory state of the retina in control 
and diabetic mice (Figure 18). 
 
Retinal cryosections were stained for the p65 subunit of NF-κB to see if NF-
κB signalling was activated by entry of p65 to the nucleus (Figure 21). Both 
control and diabetic (Figure 21 A-F) retinas were examined for co-
localisation between DAPI and NF-κB, however, there was no evidence of 
co-localisation in either case. In addition to analysis of NF-κB activation by 
IHC, WB analysis of NF-κB was also performed. Whole retinal tissue lysates 
were prepared and analysed by western blot for the ratio of phosphorylated 
NF-κB p65 to total NF-κB p65 with appropriate phospho- specific and pan 
NF-κB p65 antibodies. In contrast to NF-κB p65 analysis by IHC, the 
amount of phosphorylated NF-κB p65 was significantly increased (p<0.05) 
in lysates from diabetic retinas compared to controls (Figure 21 G-H). This 
shows that NF-κB signalling is increased in the diabetic retinas compared to 
controls. Whilst the results from these two methods of analysis are at odds, 
it is likely that the antibody preferentially binds epitopes only exposed upon 
denaturation. 
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Figure 21: Analysis of NF-κB p65 in the retinas of control and 
diabetic mice Cryosections from control (A-C) and diabetic (D-F) mice two 
months after diabetes induction were stained for Nf-κb (A, D) and DAPI (B, 
E). No meaningful evidence of Nf-κb nuclear translocation was observed in 
control or diabetic mice. Representative blots probed with antibodies to 
phosphorylated Nf-κb p65 and total Nf-κb p65 (G). Quantification of band 
intensities by normalising the intensity of phospho-p65 blots to the intensity 
of total-p65 blots (H) revealed that the amount of phosphorylated Nf-κb 
p65 was increased in diabetic retinas compared to controls. Images are 
representative of sections from 3 control and 3 diabetic mice. GCL = 
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer.   
Scale bar = 20 µm. Western blot data from three control and three diabetic 
mice. * = p<0.05. Error bars = S.E.M. 
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Vascular leakage is a key feature of diabetic retinopathy and is associated 
with progression of disease severity, being a particularly destructive 
complication of DR (Roy et al. 2017). Additionally, the onset of vascular 
leakage and development of macular edema is a clinical indication for the 
use of anti-VEGF therapeutics such as aflibercept (Cheung et al. 2010). 
Whilst no vascular leakage was detected by fluorescein angiography (Figure 
14), publications investigating vascular leakage have utilised other methods 
such as perfusion with fluorescently labelled tracers (Wang et al. 2010) and 
staining for endogenously secreted albumin (Xin et al. 2013). 
 
To examine vascular leakage in the retina in greater detail, cryosections 
were stained for IgG with a mouse-specific Alexa-Fluor-488 conjugated 
secondary antibody to label the vasculature and detect areas of vascular 
leakage. Low power images of control and diabetic (Figure 22 A, D) retinas 
two months after diabetes induction show that whilst areas of leakage were 
relatively rare in diabetic retinal sections, they were completely absent in 
sections from control retinas. High power images of control (Figure 22 B-C) 
and diabetic (Figure 22 E-F) samples reveal that whilst there was some 
positive staining for IgG in control retinas, it was limited, as expected, to 
the retinal vasculature. In contrast, in diabetic retinas there was a greater 
amount of IgG staining which appeared to result from extra-vascular IgG, 
and is therefore evidence of vascular leakage. Quantitative image analysis 
of IgG staining (Figure 22 G) revealed a 20-fold increase in IgG staining in 
diabetic retinas, however, due to the variability in IgG staining between 
samples  this observation was not statistically significant. Further analysis 
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of more samples would be required to improve the statistics in this 
experiment.  
 
Figure 22: Evidence of vascular leakage of IgG in diabetic mouse 
retinas. Two months after the induction of diabetes, retinas were isolated 
and 12 µm cryosections were stained for mouse IgG. Low power images of 
control (A) and diabetic (D) mouse retinas. White boxes shows areas of 
interest for high power images in (B-C) and (E-F). IgG staining was 
increased in diabetic (D-F) retinas compared to controls (A-C), where IgG 
staining was limited to the retinal vasculature (arrowheads). Quantitative 
image analysis of IgG staining in control and diabetic retinas (G). Images 
representative of sections from 3 control and 3 diabetic mice. GCL = 
ganglion cell layer, INL = inner nuclear layer, ONL = outer nuclear layer.  
Scale bar = 20 µm. 
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Analysis of altered GFAP expression in retinal cryosections did not reveal 
any striking differences between control and diabetic animals (Figure 18). 
Therefore, GFAP staining in mouse retinal flatmounts was analysed in order 
to investigate potential changes to astrocytes and their interaction with the 
vasculature in the diabetic retina. Flatmounted retinas were stained for both 
GFAP and collagen IV (Figure 23 A-F) and quantitative image analysis of the 
overlap between collagen IV and GFAP staining was performed to determine 
the extent of astrocyte interaction with the vasculature (Figure 23 G), 
however, there was no significant difference in the amount of GFAP overlap 
with collagen IV. Next, to analyse any changes to the distribution of 
astrocytes in the retina, binary images were generated from GFAP IF 
images and converted to show the outlines of the astrocytes (Figure 23 H-
I). The identity of the images was masked and the number of astrocytes in 
each image was manually counted (Figure 23 J). However, no significant 
difference in astrocyte number was found. 
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Figure 23: Astrocyte-endothelial cell interactions in the diabetic 
retina. Flatmounted retinas were isolated two months after the induction of 
diabetes from control (A-C) and diabetic (D-F) mice and stained for collagen 
IV and GFAP. Quantitative image analysis of the overlap of collagen IV and 
GFAP staining (G) revealed no significant difference in the degree of overlap 
of these two markers. Outlines of GFAP positive cells were generated from 
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binary images of GFAP staining (H-I). Cells were counted manually after the 
being blinded, which revealed that there was no significant difference in 
astrocyte number in control or diabetic mice (J). For analysis of collagen IV 
and GFAP overlap, 3 different images from 6 mice from each group were 
used for image analysis. For astrocyte number, one image from 6 mice from 
each group were used. Scale bar = 50 µm.  
 
Having identified an increase in extravascular IgG staining in the sections of 
diabetic retinas (Figure 22), I wanted to determine what the pattern of 
vascular leakage looked like across the whole retina. Since vascular leakage 
is not uniform across the diabetic retina, analysing tissue sections cannot 
give a complete picture of the full extent of vascular leakage. IgG has a 
relatively high molecular weight for a circulating protein, so I chose to 
examine the leakage of 40 kDa FITC-dextran as I reasoned this would be a 
more sensitive indicator of vascular leakage than endogenous IgG staining. 
FITC-dextran was intravenously administered to mice via the tail vein and 
allowed to circulate for 1 hour before mice were euthanised and retinas 
were processed for analysis by IF. However, imaging of retinas from control 
and diabetic mice revealed no evidence of vascular leakage after perfusion 
with FITC-dextran (Figure 24 A-B). In contrast, when endogenous IgG 
staining was analysed in retinal flatmounts by IF, this revealed increased 
extravascular staining for IgG in diabetic retinas (white arrowheads, Figure 
24 C-D), consistent with the data obtained from retinal sections (Figure 22). 
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Figure 24: Assessment of vascular leakage in retinal flatmounts. 
Staining for endogenous IgG revealed areas of vascular leakage in retinal 
flatmounts, that were not observed following intravenous perfusion of FITC-
dextran. Two months after the induction of diabetes, control or diabetic 
mice were perfused with 100 µg/mL of 40-kDa FITC-dextran for 1 hour, 
before being euthanised (A-B) to examine vascular leakage. Alternatively, 
flatmounted retinas were stained for endogenous IgG by IF (C-D). There 
was no evidence of extravascular FITC-dextran in diabetic retinas (B), 
however, there was an increased amount of extravascular IgG in diabetic 
retinas (white arrowheads, D) compared to control retinas (C). Scale bar = 
1 mm. Images representative of 6 mice per group.   
FITC-Dextran
IgG
C
DiabeticControl
A
D
B
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2 Gene expression in the streptozotocin-induced 
diabetic mouse retina 
Altered expression of pro-inflammatory and pro-angiogenic genes in 
diabetic retinopathy plays a key role in changes to the retinal 
microenvironment in diabetes. To examine whether gene expression was 
altered in the retinas of diabetic mice, RNA was extracted from retinas from 
diabetic mice and appropriate age-matched controls two months after 
diabetes induction and gene expression was analysed by qPCR. The role of 
some growth factors in diabetic retinopathy, such as Vegf, has been well 
characterised, whilst the roles of other genes that were examined have yet 
to be determined. Comparing the expression of Vegf with other genes such 
as angiopoietin like 2 (Angptl2), angiopoietin like 6 (Angptl6) and Lrg1 will 
help determine the roles they play in diabetic retinopathy and whether they 
might be considered as potential new therapeutic targets. 
 
As has been previously described (Bai et al. 2009), Vegf expression was 
increased in diabetic retinas compared to controls (Figure 25 A). This 
highlights the important role of Vegf and vascular leakage in diabetic 
retinopathy, and is consistent with data in Figure 22 & Figure 24. Whilst 
LRG1 is increased in the vitreous of diabetic patients, and has been 
demonstrated to promote angiogenesis and vascular leakage in vitro and in 
vivo (Wang et al. 2013), its role in animal models of diabetes has not yet 
been examined. Both Lrg1 and Tgfbeta were increased in the diabetic 
retinas (Figure 25 E-F). 
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The role of the Ang-1 and Ang-2 in regulating angiogenesis and vascular 
permeability is well established. However, the family of angiopoietin-like 
proteins (Angptl) has 9 members which signal independently of Tie1/Tie2 
receptors with various effects on the vascular endothelium (Hato et al. 
2008) and are generally less well understood. The roles of various proteins 
of this family have recently been discovered in the retina. Angptl-4 was 
shown to promote retinal vascular permeability, and was upregulated in 
hypoxic conditions (Xin et al. 2013). The roles of Angptl-2 and Angptl-6 in 
the diabetic retina have not yet been characterised, so I decided that these 
were two genes worth investigating with a potential role in diabetic 
retinopathy. 
 
Angptl2 has previously been shown to mediate inflammation in the 
endotoxin-induced uveitis model of retinal inflammation (Kanda et al. 
2012). Similarly to Vegf, Angptl2 expression was increased in diabetic 
retinas compared to controls (Figure 25 B). Angptl6 has been previously 
shown to induce angiogenesis and vascular permeability in vivo (Oike et al. 
2004). Whilst Angptl6 is predominantly expressed by the liver, an 
alternative Angptl6 transcript encoding exons 4-6 is more widely expressed 
in a number of different tissues (Hato et al. 2008). In the mouse retina, the 
relative expression of the transcript encoding exons 4-6 was approximately 
100-fold higher than the expression of the full length Angptl6 transcript 
(Figure 25 C-D). Unlike the full-length transcript (Figure 25 C), the 
transcript encoding exons 4-6 of Angptl6 was expressed at a statistically 
significantly higher level in diabetic retinas compared to controls (Figure 25 
D).  
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Figure 25: Altered gene expression in control and diabetic mouse 
retinas. RNA was extracted from control or diabetic mouse retinas for qPCR 
analysis two months after diabetes induction. qPCR showed a statistically 
significant increase in the levels of Vegf (A), Angptl2 (B), Lrg1 (E) and 
Tgfbeta (F) in diabetic retinas. Primers that targeted the full-length 
transcript for Angptl6 (C) showed there was no increase in expression of the 
full-length transcript, whilst primers that targeted the transcript of exons 4-
6 (D) showed a statistically significant increase in expression in diabetic 
mice. Additionally, expression of the shorter transcript was higher than that 
of the full-length transcript in both the control and diabetic retinas (C, D). 
Data from at least 6 experimental animals per group. Statistical analysis 
was performed using students T-test with Welch’s correction to control for 
unequal variance. * = p<0.05. ** = p<0.01.  
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3 Angptl6 
The differential expression of the two Angptl6 transcripts indicates that the 
regulation of this gene differs according to the tissue and cell type. The 
functional domains of Angptl6 appear to be present in the N-terminus of 
this protein, which indicates that both the full length and truncated isoform 
have similar biological activity. As Angptl6 expression has not previously 
been reported in the retinas of diabetic mice, I wanted to test whether its 
pro-angiogenic effect would be evident in the mouse metatarsal assay 
(Figure 26). This would enable me to further characterise the effect of 
Angptl6 on the vasculature.  
 
However, quantification of angiogenesis by analysis of CD31 staining 
revealed that treatment with 1 µg/mL of recombinant human ANGPTL6 did 
not reveal any increase in angiogenesis (Figure 26), despite this 
concentration being previously reported in the literature to be sufficient to 
induce angiogenesis (Okazaki et al. 2012; Oike et al. 2004). In contrast, 
VEGF which was used here as a positive control (Figure 26 C) showed a pro-
angiogenic response. It was disappointing to find that in our hands 
ANGPTL6 did not induce angiogenesis as had previously been reported in 
vitro and in vivo (Oike et al. 2004), although this may have been due to the 
assay utilised, or the human protein may be less bioactive on mouse cells. 
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Figure 26: Recombinant human ANGPTL6 does not promote 
angiogenesis in the mouse metatarsal assay. Metatarsals were 
cultured for 10 days in basal media or with 1 µg/mL recombinant ANGPTL6. 
Cultured metatarsals were stained for CD31 to label endothelial cells (A-C). 
CD31 staining was analysed to measure the amount of vessel sprouting and 
branching (D-E). Untreated (A) or ANGPTL6 at 1 µg/mL (B) showed no 
change in vessel formation (D) or vessel branching (E). There was 
increased angiogenesis when metatarsals were treated with 50 ng/mL of 
VEGF as a positive control (C). Data from 2 independent experiments with 
at least 12 bones per experiment. Scale bar = 500 µm. 
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4 Lrg1 
Of the various factors investigated, neither Angptl2 nor Angptl6 were 
considered to be sufficiently promising for further study. However, the 
increase in Lrg1 expression in the retinas of diabetic mice (Figure 25 E), 
together with previously published observations that LRG1 is increased in 
the vitreous of patients with PDR (Wang et al. 2013) suggests a possible 
role for Lrg1 in diabetic retinopathy. To further explore the role of Lrg1 in 
the streptozotocin mouse, diabetes was induced in Lrg1 KO mice and age-
matched WT controls to determine whether the absence of Lrg1 would alter 
the phenotype of the diabetic retina. 
 
In the first instance, fundus images were taken to examine whether there 
were any changes to the diabetic retina in Lrg1 KO mice versus WT controls 
two months after diabetes induction. Compared to WT animals (Figure 27 A-
B), the abnormal retinal phenotype appeared to be less severe in the Lrg1 
KO mice with fewer hyper-reflective spots (Figure 27 C-D). This suggests 
that Lrg1 KO mice may have a less severe diabetes-induced retinal 
phenotype. It is important to note that in this cohort, the WT diabetic mice 
(Figure 27 A-B) had a more severe retinal phenotype than their equivalent 
WT diabetic counterparts in Figure 13. It should also be noted that the Lrg1 
KO mice and their WT littermate controls (mice were bred from 
heterozygous pairs) were bred and housed in what was designated as a 
‘clean room’ in the animal facility, and hence may be more sensitive to 
diabetes-induced inflammatory activation of the immune system. 
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Figure 27: Fundus imaging in WT and Lrg1 KO diabetic mice. Two 
months after diabetes induction, fundus imaging of diabetic retinas from WT 
(A-B) and Lrg1 KO (C-D) mice revealed that the KO mice had a less severe 
diabetic phenotype (white arrowheads) in the retina, as judged by a 
reduction in the number of inflammatory infiltrates. 
 
Having shown that Lrg1 KO mice have a less severe retinal phenotype after 
the induction of diabetes, the levels of blood glucose were compared with 
WT diabetics to ensure the severity of diabetes was similar across different 
strains (Figure 28). The similar blood glucose levels show that any 
differences in retinal phenotype are therefore likely to be due to the 
different genotypes rather than differences in the severity of 
hyperglycaemia. 
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Figure 28: Blood glucose measurements in diabetic mice. Blood 
glucose was measured using a glucometer two months after diabetes 
induction. Blood glucose levels were similar in WT, Lrg1 KO and human 
LRG1 knock-in (KI) mice.  
 
Having shown that staining retinal flatmounts for endogenous IgG is a more 
reliable way of examining vascular leakage than perfusing with fluorescent 
dextrans (Figure 24) or by fluorescein angiography (Figure 17), and that 
diabetic Lrg1 KO mice apparently have a milder retinal phenotype (Figure 
27), I decided to investigate whether vascular leakage was reduced in 
diabetic Lrg1 KO mice. Retinas from WT or Lrg1 KO mice were stained for 
IgG, two months after the induction of diabetes to examine vascular 
leakage. Vascular leakage appeared to be reduced in the retinas from 
diabetic Lrg1 KO mice, compared to diabetic WT mice, comparison of the 
number of leakage foci revealed a statistically significant (p<0.05) decrease 
in the number of leakage sites in Lrg1 KO mice versus WT controls (Figure 
29). This indicates that the absence of Lrg1 attenuates diabetes-induced 
vascular leakage in the retina, in agreement with previous data which has 
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demonstrated that it plays a role in increased vascular permeability and 
angiogenesis in other disease models (Wang et al. 2013). 
 
 
Figure 29: Vascular leakage in diabetic WT and Lrg1 KO mice. 
Flatmounted retinas from WT (A) or Lrg1 KO (B) mice two months after the 
induction of diabetes were stained for endogenous IgG. The number of 
leakage foci were counted manually after being blinded to the identify of the 
images (C), which revealed a statistically significant decrease in the sites of 
vascular leakage in Lrg1 KO mice. Representative images from 6-7 mice per 
genotype. Scale bar = 1 mm. Statistical analysis was performed using 
students T-test. * = p<0.05. 
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Having shown that diabetes-induced retinal vascular leakage is attenuated 
in the Lrg1 KO mice, I sought to examine the effect of diabetes on the 
human LRG1 knock-in (KI) mouse. This KI mouse was generated in order to 
test the efficacy of a humanised LRG1 blocking antibody as a potential 
therapeutic, as the antibody does not cross-react with the mouse protein. 
Additionally the human LRG1 transgene is flanked by LoxP sequences, 
which allows it to be deleted by the CRE recombinase, permitting cell/tissue 
specific deletion of the gene. The ability to conditionally knock out the gene 
in the mouse would therefore allow further mechanistic insight of the role of 
Lrg1 in the retina. 
 
Since human LRG1 KI mice have an increased blood glucose level after 
diabetes induction, similar to Lrg1 KO and WT mice (Figure 28), one would 
expect these mice to respond in a similar manner as WT mice to the 
induction of diabetes. Vascular leakage was analysed two months after the 
induction of diabetes in hLRG1 KI mice (Figure 30). IgG staining revealed 
that diabetic hLRG1 KI mice had increased vascular leakage compared to 
age-matched non-diabetic controls, as has been previously demonstrated in 
WT mice. This shows that hLRG1 KI mice develop a similar retinal 
phenotype in response to streptozotocin-induced diabetes as occurs in WT 
mice. Another advantage of this mouse strain is its compatibility with the 
human LRG1 ELISA to detect changes in the level of LRG1 protein in the 
retina, as there is a lack of suitable reagents to develop a mouse Lrg1 
ELISA. Having previously demonstrated by qPCR that Lrg1 is upregulated in 
the mouse retina (Figure 25 E), I sought to demonstrate that LRG1 protein 
is also upregulated in the diabetic LRG1 KI retina. Although an ELISA was 
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performed to analyse LRG1 in control and diabetic mouse retinas, the 
concentration of LRG1 in whole retinal lysates was below the lower limit of 
detection of this assay. 
 
 
Figure 30: Human LRG1 KI mice develop symptoms of diabetic 
retinopathy similarly to WT mice. Vascular leakage was analysed by 
endogenous IgG staining two months after diabetes induction in control (A) 
or diabetic (B) LRG1 KI mice. Images representative of 4 mice per 
condition. Scale bar = 1 mm.  
 
In summary, work in this chapter has shown that although the 
streptozotocin mouse fails to develop the severe retinal phenotype observed 
in other models and strains, it does nevertheless exhibit a wide range of 
sub-pathological changes. As a tool for investigating early changes this 
model therefore offers several advantages, since a primary goal of 
therapeutic intervention in human disease is the prophylactic control of PDR 
and DME in patients already at risk. 
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Chapter 5 
Discussion 
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1 Effect of hyperglycaemia on angiogenesis in vitro 
In the first instance, the aim of the work in this thesis was to investigate 
the effects of hyperglycaemia on the vasculature in vitro, using the 
metatarsal assay. One of the major limitations of in vitro angiogenesis 
assays is that it is difficult to recreate the complex intercellular interactions 
between different cell types and the structural ECM components that exist 
in vivo. To address these limiting factors, the embryonic mouse metatarsal 
assay is an effective ex vivo model of the vasculature, which acts as a 
compromise between a simpler in vitro study with cultured cells and a more 
complex in vivo one (Song et al. 2015). 
 
These studies in the metatarsal assay involving the supplementation of 
culture media with additional levels of glucose showed that high glucose 
treatment (25 mM) led to a reduction in angiogenesis. Prior to the 
development of neovascularisation in diabetic retinopathy, the behaviour of 
the vasculature and the endothelial cells is altered. Whether these changes 
are due to the direct effect of elevated blood glucose or glycated protein 
adducts on the endothelial cells themselves, or elicited by paracrine 
mediators from surrounding cells has not been firmly established, although 
it is feasible that all play a role. 
 
In this assay, high glucose did not induce changes in the ratio of pericyte-
endothelial cell staining, which is known to be reduced in the diabetic retina 
(Pfister et al. 2008). This implies that in this assay, high glucose may 
primarily alter the behaviour of endothelial cells rather than the perivascular 
cells. However, effects on other perivascular cells, such as smooth muscle 
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cells, macrophages and fibroblasts, may also occur in response to high 
glucose but these were not examined in this study. Whilst the relationship 
between endothelial cells and pericytes has been well characterised, 
especially in the context of diabetic retinopathy, less is known about the 
role of the other perivascular cells and their association with diabetes 
induced changes to the retinal vasculature. Further work to investigate 
these changes could identify key cellular changes in diabetes and expand 
the knowledge in this area of research. Since many of these cells are 
present in the metatarsal assay, this would be an ideal model system to 
investigate this, as high glucose and other diabetic insults could be used to 
induce these changes a the cellular level. 
 
One explanation for the reduction in angiogenesis may be due to high 
glucose induced upregulation of the Notch ligand, Jagged 1 (Jag-1), as has 
been previously described in a co-culture model of endothelial cells and 
smooth muscle cells (Yoon et al. 2014). Jag-1 is pro-angiogenic during 
development, and antagonises the notch ligand Delta-like 4 (Dll4), which 
attenuates Dll4/Notch mediated vessel stabilisation and maturation 
(Benedito et al. 2009). The high glucose-induced increase in Jag-1 was 
accompanied by an initial increase in sprouting and branching of unstable 
vessel sprouts which later regressed, unlike cultures treated with mannitol 
which sprouted normally (Yoon et al. 2014). Jag-1 has also been 
demonstrated to play a role in diabetes-induced capillary degeneration in 
the retina and myocardium, EC specific knockdown of Jag-1 led to a 
reduction in diabetes-induced capillary degeneration (Yoon et al. 2016). 
However, another group has shown that Jag-1 is decreased in smooth-
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muscle cells in hyperglycaemia which is anti-angiogenic (Lee et al. 2016). 
Therefore one could expect Jag-1 to behave differently according to the cell 
type and context. Whilst Jag-1 is pro-angiogenic during development, its 
aberrant activation in the mature vasculature in pathological conditions 
leads to the disruption of the vasculature.  
 
High glucose caused a statistically significant reduction in Vegf secretion in 
the metatarsal assay, in agreement with other reports where Vegf was 
reduced in endothelial cells exposed to high glucose (Yang et al. 2008; Yu 
et al. 2016). Compared to these other reports, the reduction in Vegf in 
response to high glucose was relatively modest, with approximately 25% 
reduction in Vegf secretion observed in this data set compared to a 75% 
decrease as reported by (Yang et al. 2008; Yu et al. 2016). Whether or not 
a 25% reduction in Vegf production has a physiological function remains 
unclear, to determine this, one could titrate in exogenous Vegf to see if it 
alters the level of angiogenesis in the metatarsal assay. However, high 
glucose treatment has been shown to induce Vegf in other cell types such 
as fibroblasts, smooth muscle cells and pericytes (Doronzo et al. 2012; Tsai 
et al. 2013; Giurdanella et al. 2015). Therefore, it is plausible that high 
glucose could be decreasing Vegf expression in the endothelial cells in this 
assay whilst increasing Vegf expression in other cell types. This could 
explain why a modest decrease in Vegf secretion was observed. To 
determine the effect of high glucose on Vegf expression in different cell 
types, fluorescent in situ hybridisation could be used to identify which cell 
types express Vegf. 
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One of the consequences of reduced Vegf production specifically in 
endothelial cells is an increase in apoptosis (Yang et al. 2008). Endothelial 
cell specific deletion of VEGF leads to a decrease in survival, which cannot 
be compensated for by paracrine derived Vegf (Lee et al. 2007). 
Additionally, treating endothelial cells with a VEGFR2 inhibitor led to a 
decrease in cell survival which was not observed upon treatment with a 
VEGF blocking antibody (Lee et al. 2007). This highlights the important role 
for autocrine Vegf signalling in endothelial cell survival and for maintaining 
the vasculature. Additionally this implies that VEGFR2 signalling activates 
different signalling pathways depending on whether the receptor is 
activated at the plasma membrane or intracellularly. To determine whether 
high glucose treatment alters autocrine Vegf signalling, one could look at 
VEGFR2 activation by western blotting or immunofluorescence. 
 
It is possible that the observations in this study may have more relevance 
to other diabetic vascular complications such as peripheral vascular disease 
and impaired wound healing, which is characterized by insufficient 
angiogenesis and a reduction in VEGF (Wirostko et al. 2008). Further 
studies on the potential role of high glucose-induced alterations to 
angiogenesis in the metatarsal assay with this in mind will allow further 
exploration of this idea.  
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2 Effect of AGE-BSA on angiogenesis in the 
metatarsal assay 
Whilst elevated blood glucose is the underlying cause of vascular 
complications arising in diabetic patients, supplementing cell culture media 
with additional glucose does not fully recreate the diabetes-induced changes 
the vasculature is exposed to in vivo. Formation of advanced glycation end-
products (AGEs) is an important post-translational modification that occurs 
in diabetic patients (Barlovic et al. 2011). AGEs form in vivo through three 
main mechanisms; the Maillard reaction, the polyol pathway and lipid 
peroxidation (Ott et al. 2014). AGE deposition occurs on circulating 
proteins, the plasma membrane and intracellularly, meaning that diabetes-
induced increase in AGE formation modifies extracellular and intracellular 
proteins and other macromolecules.  
 
There are multiple receptors for AGE, which play different functions. Some 
receptors such as macrophage scavenger receptor and CD36, are involved 
in the uptake of extracellular AGEs (Araki et al. 1995; Ohgami et al. 2002) 
which  internalises AGEs for detoxification in the lysosome (Grimm et al. 
2012). The increase in extracellular AGEs may therefore lead to the 
accumulation of pathologically high levels of intracellular AGEs, which 
cannot be degraded. Another important receptor which responds to AGEs is 
the receptor for advanced glycation end products (RAGE), which plays a key 
role in activating AGE-induced inflammatory signalling via JAK/STAT, ROS, 
NF-κB and MAPKs (Ott et al. 2014). Of the many different receptors for 
AGE, RAGE is the best understood (Ott et al. 2014), and is the only AGE 
receptor which has been linked to different vascular complications of 
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diabetes (Li et al. 2011). Based on the current understanding of AGE 
signalling and the RAGE mediated pro-inflammatory signalling pathways 
AGE/RAGE signalling is likely to be the primary mechanism for AGE induced 
pathology in the vasculature and surrounding tissue in diabetes. 
 
Measuring AGE deposition on haemoglobin has superseded blood glucose 
measurements in the clinic as a biomarker for diabetes severity 
(Sabanayagam et al. 2009), and whilst AGE deposition on haemoglobin is 
unlikely to make a significant contribution to AGE/RAGE signalling in 
endothelial cells and other cell types, it is a useful indicator for the severity 
of diabetes. Another circulating protein which is modified by AGE deposition 
is albumin, which has also been linked in the clinic to the severity of 
diabetes (Vetter 2015). The clinical association of glycated albumin with 
diabetes and its abundant and free circulation in plasma means that AGE-
BSA is a physiologically relevant reagent for studying the effects of AGE. 
Additionally glycated albumin is a widely used reagent to study the effect of 
AGEs on the vasculature (Yamagishi et al. 1997; Popov & Simionescu 2006; 
Wu et al. 2014; Zhang et al. 2015). This means AGE-BSA is a suitable 
reagent for studying the effects of increased AGE formation on angiogenesis 
in the metatarsal assay. 
 
Treatment with AGE-BSA led to statistically significant increases in 
angiogenesis, Vegf secretion and the expression of other pro-angiogenic 
growth factors, including Il-6. This implies that AGE-BSA induces both 
angiogenesis and inflammation, the combination of which has been linked to 
a variety of pathological conditions, including diabetes (Costa et al. 2007; 
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Kim et al. 2013; West et al. 2010). Also the results from these experiments 
fit with previous reports which have shown that AGE-BSA is pro-angiogenic 
and induces VEGF expression in vitro and in vivo (Yamagishi et al. 1997; 
Mamputu & Renier 2004; Cohen et al. 2005). Whilst RAGE activation is the 
most likely cause of increased angiogenesis and growth factor induction in 
these experiments (Ott et al. 2014), these studies have not resolved 
whether AGEs from exogenously added AGE-BSA are the sole driver of the 
altered phenotype in the metatarsal assay, or whether macromolecules on 
the plasma membrane have also been modified by AGEs or whether AGEs 
have been internalised by the endothelial cells or other perivascular cells. 
There is evidence from some in vivo studies that AGE-modified albumin is 
internalised into cells at a higher rate than native albumin in the brain 
vasculature (Vorbrodt & Dobrogowska 1999), it is therefore plausible that 
intracellular accumulation of AGE-BSA will occur at a greater rate than 
native albumin, and that this may have significant effects on the 
intracellular environment, in addition to the well characterised 
consequences of extracellularly activating RAGE. 
 
Both previous reports and data in this thesis show that AGEs promote 
angiogenesis. In addition to this, they also appear to promote vascular 
leakage in vitro and in vivo (Esposito et al. 1989; Boyd-White & Williams 
1996; Zhang et al. 2015; Wu et al. 2014). There is evidence that AGEs can 
induce permeability through multiple mechanisms, such as modification of 
the basement membrane (Boyd-White & Williams 1996) and increased 
paracellular permeability through Src dependent VE-cadherin 
phosphorylation (Zhang et al. 2015). Inhibition of Src has also been shown 
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to attenuate diabetes-induced retinal vascular permeability and VE-cadherin 
internalisation in the diabetic rat (Kim & Suh 2017). Studies with 
radiolabelled AGE-BSA have shown that AGE receptors are localised to 
caveolin-rich membrane domains (Stitt et al. 2000). Caveolae are 
associated with increased transcellular permeability in the vascular 
endothelium and are involved with the organisation of receptors to distinct 
regions at the plasma membrane and intracellularly within vesicles (Bastiani 
& Parton 2010). Since AGEs induce the upregulation of RAGE (Stirban et al. 
2014), could AGE-mediated RAGE upregulation lead to an increase in the 
number of caveolae? Since caveolae are also involved in mediating 
transcellular vascular permeability (Guo et al. 2016), AGE/RAGE signalling 
may therefore increase the number of caveolae, which has been shown to 
mediate Vegf induced permeability in the retina (Hofman et al. 2000).  
 
Plvap is a marker associated with increased vascular permeability and is 
expressed on caveolae, and its expression is linked with increased vascular 
permeability in pathological conditions (Guo et al. 2016). The effect of AGE-
BSA treatment on Plvap was analysed by immunofluorescence and qPCR, 
however, Plvap appeared to be constitutively expressed with no changes 
observed in either condition. Previous reports that AGE-BSA stimulated an 
increase in vascular permeability were conducted on endothelial cells grown 
as a monolayer (Esposito et al. 1989; X.-Y. Zhao et al. 2015). It is possible 
that the endothelial cells in the metatarsal assay are not sufficiently 
polarised, which may influence how they respond to permeability-inducing 
agents. Therefore further investigation in vitro of the permeability inducing 
effects of AGE-BSA should be considered using endothelial cells grown in a 
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monolayer. Further work could also be performed to ask whether AGE-BSA 
induces Src activation and disruption of VE-cadherin in this assay.  
 
Since AGE-BSA is known to activate JAK/STAT signalling downstream of 
RAGE (Stirban et al. 2014) and was shown to induce Il-6 in this assay, 
which has previously been shown to mediate pathological angiogenesis 
(Gopinathan et al. 2015), I felt this warranted further investigation. To see 
if the increase in Il-6 was accompanied by an increase in JAK/STAT 
signalling, which induces the transcription of pro-inflammatory and pro-
angiogenic genes (Scheller et al. 2011), pSTAT3 levels were analysed by IF, 
and appeared to be increased in AGE-BSA treated metatarsals. However, 
this was the result of only one independent experiment and the lack of 
nuclear-specific pSTAT3 staining raises questions about the specificity of the 
antibody. Nevertheless, it is possible that AGE-BSA directly increases 
JAK/STAT signalling via RAGE dependent signalling (Xie et al. 2013), which 
may also be enhanced by the induction of Il-6 (Scheller et al. 2011) through 
other signalling pathways.  
 
The data presented in this thesis, in agreement with the literature implies 
that hyperglycaemia mediates a dysfunctional phenotype in endothelial cells 
associated with decreased Vegf production and angiogenesis, which may be 
associated with a reduction in pro-survival signalling in endothelial cells (Yu 
et al. 2016; Busik et al. 2008; Doronzo et al. 2012). In contrast to this, 
treatment with AGE-BSA is pro-angiogenic, increases Vegf production and 
appears to bear similarities with angiogenesis in the context of inflammation 
(Costa et al. 2007). Neither high glucose treatment nor AGE-BSA alone 
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would be expected to recreate all the effects of diabetes on vascular 
function that occur in the retina, although a combined treatment of high 
glucose and AGE-BSA may better represent diabetes-induced vascular 
changes in the metatarsal model, since the studies in the metatarsal assay 
have demonstrated that both treatments have very different effects. 
Despite this, such models have value in that they permit the molecular 
dissection of the contributions made by individual components of the 
diabetic phenotype. 
 
One drawback of these studies in the metatarsal assay is that the same 
dose and treatment regimen was used. Whilst the concentrations used in 
these experiments follow what has been previously published in the 
literature and has demonstrated to be effective in eliciting a physiological 
response in various in vitro assays, neither AGE-BSA or high glucose have 
been administered to the metatarsal assay or other truly similar model 
before. Therefore some experiments to examine a dose response to both 
AGE-BSA and high glucose would be useful to find the optimal concentration 
of both treatments. For example, whilst AGE-BSA is often used at a 
concentration of 100-500 µg/mL, the concentration of glycated albumin in 
patients with type 1 diabetes reaches 30 mg/mL (Nathan et al. 2011). 
Therefore there is a rationale for increasing the concentration of this 
treatment further whilst still being physiologically relevant. Additionally, if 
changes to gene expression and angiogenesis occur in a dose dependent 
manner then it confirms that this response is specific to the treatment. 
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Another variable to investigate would be the response with time, for both 
treatments it would be useful to know whether the phenotype increases in 
severity the longer the cultures are treated for and whether the response 
changes. For example, there may be a different acute response after the 
first few days of treatment with either high glucose or AGE-BSA, which 
could change towards the end of the experiment. In addition to 
investigating the response over time, investigating whether the phenotype 
in response to either treatment is reversed when it is removed would hold 
important functional relevance. In diabetic patients, blood glucose levels are 
not uniform and fluctuate throughout the day, there is also evidence that 
high glucose can exert long term epigenetic changes on endothelial cells 
even after a return to normal levels of glycaemia (Hammes et al. 2011). As 
a result it would be worth investigating whether high glucose or AGE-BSA 
can mediate long term changes to the vasculature in this model. 
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3 Analysis of the diabetic mouse retina 
The general consensus presented here in this thesis and in the literature is 
that in vitro and ex vivo approaches are useful for studying the vasculature, 
and play a role in the investigation of some diabetes-induced changes to the 
vasculature. However, they are unable to fully recreate the complex nature 
of the vasculature in living tissue. Rodent models of diabetes such as the 
streptozotocin induced rat and mouse are widely used to investigate 
diabetes-induced changes to the retina (Lai & Lo 2013). Whilst the 
streptozotocin rat shows a more severe retinal phenotype in a shorter 
timeframe after the induction of diabetes, the major drawback of this 
animal model is that it limits the use of various transgenic models that are 
primarily available in the mouse. Genetic models of diabetes that exist in 
the mouse include the Ins2Akita (Barber et al. 2005) db/db (Bogdanov et al. 
2014) and Akimba (Wisniewska-Kruk et al. 2014) mouse, all of which show 
more extensive diabetes-induced changes to the retina than the 
streptozotocin mouse, and in particular more pronounced change to the 
retinal vasculature. Whilst the Akimba mouse model exhibits extensive 
vascular changes such as severe leakage and neovascularisation, the 
relevance of this model is questionable since it involves the overexpression 
of Vegf in the photoreceptors (Wisniewska-Kruk et al. 2014). Both the 
db/db and Ins2Akita mice show evidence of increased vascular permeability, 
however, the db/db mouse has been reported to show more 
neurodegenerative features associated with diabetic retinopathy (Bogdanov 
et al. 2014), which were not observed in the Ins2Akita mouse (Barber et al. 
2005). However, microglial activation, reduced astrocyte interaction with 
the vasculature and altered occludin distribution have been reported in the 
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Ins2Akita mouse (Barber et al. 2005) which have not been reported in the 
db/db mouse.  
 
Although the streptozotocin mouse model of diabetes has a less severe 
retinal phenotype than the db/db and Ins2Akita mouse models, the ability to 
readily induce diabetes in existing transgenic mouse models is a useful tool 
for examining the roles of different genes in the pathogenesis of diabetic 
retinopathy. Additionally, since one of the aims of this thesis was to 
investigate early diabetes-induced changes to the retina, the streptozotocin-
induced mouse is ideal for studying minor changes to the retina. 
 
Analysis of the diabetic mouse retina by in vivo imaging and 
immunohistochemistry revealed, as expected, modest changes to the 
diabetic retina, consistent with previous reports of minor diabetes-induced 
changes to the retina in this model (Feit-Leichman et al. 2005; Martin et al. 
2004; Lai & Lo 2013). Examination by fundus imaging showed a subtle 
retinal phenotype with some hyper-reflective spots, which are generally 
taken to indicate the presence of inflammatory infiltrates, with no changes 
detected by fluorescein angiography. The lack of observable changes to the 
vasculature by fluorescein angiography analysis is not surprising after just 
two months of diabetes, so more detailed analysis was performed on tissue 
sections and retinal flatmounts. These investigations revealed vascular 
leakage in diabetic retinas, as judged by staining for endogenous IgG, but 
not for intravenously administered fluorescein or FITC-dextran. This was 
unexpected, considering the differences in size between fluorescein (1 kDa), 
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dextran (40 kDa) and IgG (155 kDa), and given that the lower molecular 
weight reporters should readily leak from any compromised vasculature. 
 
There are two likely reasons for the disparity in the data from the different 
methods used. Firstly, imaging by fluorescein angiography (FA) was only 
recorded up to 10 minutes after the subcutaneous administration of 
fluorescein, although short time points are unavoidable because of the rapid 
clearance of fluorescein from the circulation. Other studies have used 
similar time-points for the analysis of vascular leakage in the laser-induced 
choroidal neovascularisation (CNV) model of AMD (Takeda et al. 2009). 
Since the CNV model produces a small focused area of intense leakage and 
neovascularisation and is thus well-suited to FA, this method and time-point 
may not be sensitive enough to detect the more modest levels of vascular 
leakage in the diabetic retina. This may also explain why FITC-dextran 
perfusion (1 hour) similarly failed to reveal any areas of leakage, as one 
hour may not have been long enough to allow sufficient extravasation of the 
fluorescent tracer. 
 
A second possible explanation is that since the conditions in the retina are 
likely to be dynamic and constantly changing, the permeability of the retinal 
vasculature may also vary with natural fluctuations in blood glucose levels 
and diurnal alterations in vascular permeability possibly due to dark-induced 
stress on the retina (Arden et al. 1998). Whilst any endogenous 
extravasated IgG is likely to be slowly broken down and cleared from the 
retina, measuring the level of an endogenous marker of vascular leakage 
permits analysis over a longer time period than a snapshot obtained with 
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exogenous tracers, and will detect episodes and sites of transient vascular 
permeability. Sacrificing mice at other times during the day such as one 
hour after light onset or during darkness may also reveal a retinal 
phenotype with increased vascular leakage. However, it is not clear how 
specific this predicted increase in vascular leakage would be to the diabetic 
retina. 
 
Aside from vascular leakage, other markers of altered retinal phenotype 
were analysed. GFAP is constitutively expressed in astrocytes and 
expressed in Müller cells during periods of retinal stress (de Hoz et al. 
2016). However, staining retinal sections revealed only minor changes in 
GFAP expression in diabetic animals. It has been reported that GFAP 
expression is increased in Müller cells in the diabetic rat (Ly et al. 2011) and 
the db/db diabetic mouse (Bogdanov et al., 2014), and whilst there is one 
report of increased GFAP in the streptozotocin mouse retina (Feit-Leichman 
et al. 2005), this was analysed by western blot, which does not indicate in 
what cell type the increase occurred, and was transient as GFAP returned to 
basal levels after the initial increase at one month post diabetes induction. 
Based on the lack of convincing changes alterations to GFAP in the retina of 
the streptozotocin mouse, it is possible that increased GFAP expression in 
the Müller cell does not occur in this model at this early stage. 
 
Since analysis of the sectioned diabetic mouse retina revealed little 
evidence of GFAP expression in Müller cells, retinal flatmounts were 
analysed for changes in astrocytes and their interaction with the retinal 
vasculature. In contrast to observations reported in the diabetic rat retina 
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(Ly et al. 2011; Barber et al. 2000) and Ins2Akita mouse (Barber et al. 
2005), no significant or observable changes in the numbers of astrocytes or 
their interaction with the vasculature were observed. The lack of any visible 
changes in the biology of the retinal macroglia is surprising, as 
neurovascular coupling plays a key role in maintaining the blood-retinal 
barrier (Antonetti et al. 2006), and since endogenous IgG staining revealed 
clear evidence of vascular leakage, it was surprising to find no disturbance 
of altered glial-endothelial cell interactions. The observations here in the 
mouse are in contrast with data from the streptozotocin rat and Ins2Akita 
mouse that revealed a decrease in GFAP in the astrocytes (Barber et al. 
2005; Ly et al. 2011; Barber et al. 2000). One thing this study may imply is 
that changes to the retinal macroglia are transient, and only occur during 
the very early stages of diabetes and rapidly resolve. 
 
Whilst changes to the vasculature are important indicators of the health of 
the retina in diabetes, other changes may precede more noticeable 
alterations to the vasculature, and of particular importance are those that 
are associated with and promote inflammation. Microglia are resident 
immune cells in the retina and CNS, and become activated in response to 
inflammatory stimuli (Tang & Kern 2011). Inhibition of microglial activation 
has been demonstrated to reduce inflammation in the diabetic rat retina 
(Krady et al. 2005), which suggests they play an important role in 
mediating diabetes-induced inflammation in the retina. In diabetic mouse 
retinas, Iba1 expressing cells, which are likely to either be resident 
microglia or blood derived macrophages, had adopted an amoeboid 
structure and appeared to be migrating into the inner nuclear and ganglion 
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cell layers. This change in Iba1+ cell morphology has also been described in 
the Ins2Akita mouse (Barber et al. 2005), however, since this was analysed 
in retinal flatmounts, it does not so readily show the migration between 
different layer of the retina. Migrating microglia/macrophages have also 
been shown to migrate to the ganglion cell and outer plexiform layers of the 
rat retina in diabetes (Stitt et al. 2016), in agreement with data in this 
thesis. 
 
Oxidative stress is considered to be a hallmark feature of diabetes-induced 
vascular dysfunction (Giacco & Brownlee 2010), and has long been 
acknowledged to mediate the pathophysiology of diabetic retinopathy 
(Kowluru & Chan 2007). Since oxidative stress plays such an important role 
in diabetic retinopathy I decided to investigate this by immunofluorescence 
analysis of 4-HNE, a marker of lipid peroxidation. Staining for 4-HNE 
revealed an increase in immunoreactivity in diabetic retinal sections that 
was particularly evident in the photoreceptor layer. This is in agreement 
with a previous report that showed photoreceptors contribute to diabetes-
induced oxidative stress (Du et al. 2013). It is also unsurprising to see the 
greatest amount of oxidative stress in photoreceptors, since they have the 
highest metabolic activity in the retina (Kern & Berkowitz 2015) and are 
abundant in mitochondria which are a major producer of superoxide, a 
strong oxidising agent (Kanwar et al. 2007). Additionally, photoreceptors 
outer segments are formed of stacks of folded membrane which contains 
the light-sensing GPCR rhodopsin (Kocaoglu et al. 2016). The membrane-
rich nature of the photoreceptor means there is an abundance of lipids, 
which can become peroxidated.  
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Activation of the Nf-κb signalling pathway is a common feature of 
inflammation and drives the expression of classic pro-inflammatory genes 
such as Il-1β, Il-6 and Tnf-α (Lawrence 2009). To examine inflammatory 
changes in the diabetic retina, and localise these changes within the retina, 
analysis of Nf-κb activation was performed. Although no evidence of Nf-κb 
signalling was revealed by immunofluorescence analysis of phospho-p65, 
western blotting indeed revealed an increase in Nf-κb phosphorylation in the 
diabetic retina. In agreement with data in this thesis, an increase in Nf-κb 
phosphorylation by western blot analysis has also been reported by others 
in the streptozotocin mouse two months after diabetes induction (Wang et 
al. 2010). Whilst the results clearly differ between the two methods of 
analysis in this thesis, this was most likely due to the antibody exhibiting 
greater affinity and specificity for an epitope(s) in the denatured protein. In 
addition, it is possible that the antibody failed to adequately penetrate 
through to the nucleus in the retinal sections to permit detection of the p65 
subunit. Nevertheless, both immunofluorescence analysis of Iba1 staining 
and western blotting of Nf-κb provided evidence of a pro-inflammatory state 
in the diabetic retina which is consistent with the involvement of both Nf-κb 
signalling and activated microglia in the pathophysiology of diabetic 
retinopathy prior to the development of vascular leakage. The data 
presented in this thesis and by others (Wang et al. 2010; Joussen et al. 
2001; Du et al. 2013) show that inflammation is a key first step in the early 
stages of diabetic retinopathy, and therefore may be an effective 
therapeutic target for the early stages of diabetic retinopathy.  
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4 Altered gene expression in the diabetic mouse 
retina 
To identify factors that could potentially mediate diabetes-induced changes 
to the retina, qPCR analysis was used to examine changes in gene 
expression. As expected, Vegf expression was increased in the diabetic 
retina, consistent with its well established and central role in promoting 
vascular leakage (Salam et al. 2011; Bai et al. 2009; Wang et al. 2010; 
Simó et al. 2014). Of greater interest here, given the objective of 
identifying novel candidate therapeutic targets, other factors such as 
Angptl2, Angptl6, Lrg1 and Tgfβ were also upregulated in the diabetic 
retina. As previously discussed all these factors have effects on the 
vasculature, and may play a role in the pathophysiology of diabetic 
retinopathy. It is also interesting to note differences in the standard 
distribution of data from control and diabetic mice. The increase in standard 
deviation in diabetic mice compared to controls shows that despite the 
same genetic background, altered gene expression in diabetes varies 
significantly between individual animals. This may in turn correlate with a 
wide variation in the extent of any retinal pathology, and is not dissimilar to 
the situation in patients with diabetes where there is a broad spectrum of 
retinal disease. 
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4.1 Angptl6 
The increase in expression of several genes during this early stage of 
diabetes in the mouse retina shows that diabetes induces altered gene 
expression prior to the onset of any physical changes to the retina. Further 
work to establish the exact roles of these upregulated genes in the diabetic 
retina would improve our understanding of the early stages of the 
pathophysiology of diabetic retinopathy. In the first instance, I decided to 
explore the role of Angptl6 on the vasculature in more detail, since little is 
known about its effect on the vasculature, apart from the fact it induces 
endothelial cell migration and vascular permeability (Oike et al. 2004; 
Okazaki et al. 2012). In order to do this, I utilised the mouse metatarsal 
assay, due to the merits of this assay which have been discussed earlier in 
this chapter and elsewhere (Deckers et al. 2001; Song et al. 2015).  
 
However, ANGPTL6 did not increase angiogenesis in this assay, unlike 
VEGF, which was used as a positive control. Whilst this finding contradicts 
previously published reports demonstrating ANGPTL6 to be pro-angiogenic 
both in vitro and in vivo (Oike et al. 2004), there may be several reasons 
for the absence of a response in the metatarsal assay. First of all, the 
authors who initially reported the pro-angiogenic effects of Angptl6 
produced the recombinant mouse protein in house, whilst only the human 
recombinant protein is commercially available. Whilst mouse and human 
recombinant proteins are frequently used interchangeably, it is plausible 
that the recombinant human protein has reduced activity on mouse cells. 
The receptors specific for the Angptl growth factors have not been as well 
characterised as those for the angiopoietins, but Angptl6 has been shown to 
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signal through certain RGD-containing integrins, this RGD motif is 
conserved in the human and rodent orthologues (Zhang et al. 2006). 
Conservation of this motif implies that binding to these integrins is critical to 
the biology of this growth factor. The expression of different integrins has 
not been investigated in the metatarsal assay, however, two RGD binding 
integrins α5β1 (Kim et al. 2000) and αVβ3 (Brooks et al. 1994) have been 
shown to be essential for angiogenesis in vivo so would be expected to be 
expressed in the metatarsal assay. Additionally, half of all known integrins 
bind to the RGD motif (Ruoslahti 1996), so it is likely that the metatarsal 
expresses at least some integrins capable of recognising ANGPTL6, which 
means it is therefore surprising that this growth factor did not induce 
angiogenesis. However, it is important to note that by culturing the 
embryonic bones on a gelatin-coated tissue culture plate, this may 
artificially alter the expression of integrins on endothelial cells compared to 
what is found in other conditions and/or in vivo, which may in turn impair 
the ability of endothelial cells to respond to ANGPTL6. 
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4.2 Lrg1 
Whilst Angptl6 expression was increased in the diabetic mouse retina, 
further work to elucidate its functional role had limited success. 
Experiments in the metatarsal assay failed to demonstrate its ability to 
induce angiogenesis, and experiments in cultured endothelial cells (HUVEC 
and primary mouse brain derived endothelial cells) failed to identify any 
striking changes to cell signalling associated with angiogenesis 
(experiments not shown in this thesis). Whilst further work could have been 
pursued, such as using inhibitors or knock out mice to investigate the effect 
of inhibiting the endogenously produced protein or the sourcing of the 
recombinant protein from another source to confirm its efficacy, other lines 
of research were pursued instead.  
 
Whilst LRG1 has been described as a pro-angiogenic and vascular 
permeability inducing factor which is increased in the vitreous of patients 
with proliferative diabetic retinopathy (Wang et al. 2013), its potential role 
in mediating early changes in the pathophysiology of diabetic retinopathy 
has not been explored. Since other members of the lab have researched the 
role of this protein in mouse models of Age-related macular degeneration 
(AMD), another leading cause of blindness similar, its role in diabetic 
retinopathy was of relevant interest. Additionally since the recombinant 
protein, blocking antibody and knockout mouse are readily available to use 
this allows a greater number of functional experiments to be readily 
performed. 
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LRG1 exerts its effect by activating the TGF-β angiogenic switch, whereby it 
alters the conformation of the TGF-β receptor complex from TGFβR2/ALK5 
to TGFβR2/ALK1/Endoglin. The change in conformation of the receptor 
complex alters downstream signalling from Smads 2 and 3, which promote 
vascular quiescence, to Smads 1, 5, and 8, which is pro-angiogenic. Due to 
context of TGFβ signalling (Pardali et al. 2010), wholesale blockade of TGFβ 
signalling would be inappropriate. In fact, deletion of Tgfβr2 in the eye 
induced severe vascular defects characteristic of diabetic retinopathy 
(Braunger et al. 2015), implying that TGFβ signalling plays a role in 
maintaining the integrity of the retinal vasculature. Therefore, targeting 
LRG1, which is specifically involved in mediating pro-angiogenic TGFβ 
signalling, is less likely to have deleterious effects, in contrast to TGFß or 
VEGF blockade. 
 
Having shown that Lrg1 is upregulated along with Tgfbeta in the diabetic 
mouse retina, the role of Lrg1 warranted further investigation. Fundus 
imaging was initially used to allow the retinas of diabetic Lrg1 KO and WT 
mice to be examined non-invasively. As is characteristic of this model, the 
retinas exhibited patchy bright spots typical of inflammatory infiltrates, 
though this phenotype appeared to be less severe in the Lrg1 KO mice. To 
determine whether diabetic Lrg1 KO mice had reduced vascular leakage 
compared to WT mice, flatmounted retinas were stained for endogenous 
IgG. Imaging of the retinas revealed that there were fewer focal regions of 
vascular leakage in diabetic Lrg1 KO mice compared to diabetic WT. These 
observations are consistent with the known function of Lrg1 as a pro-
angiogenic, pro-permeability factor (Wang et al., 2013), and suggest that 
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loss or inhibition of Lrg1 may be protective against diabetes-induced 
vascular leakage in the mouse retina. In future studies it would be 
interesting to see if Lrg1 KO mice also had reduced Nf-κb activation, 
microglial activation or reduced oxidative stress, and whether in the diabetic 
Lrg1 KO mice there were any changes in the induction of Vegf and Angptl2 
and 6. If so, this would support the idea that Lrg1 plays a role in the 
pathophysiology of diabetic retinopathy prior to the onset of vascular 
dysfunction, and suggests that LRG1 blockade in patients prior to the onset 
of vascular symptoms may limit progression of the disease.  
 
Since Lrg1 KO mice presented a less severe retinal phenotype in diabetes, I 
sought to investigate the effects of diabetes on the retinas of human LRG1 
knock-in (KI) mice. A lack of suitable reagents had prevented me from 
confirming at the protein level that Lrg1 was increased in the diabetic retina 
in WT mice, but the hLRG1 KI mice might allow analysis of LRG1 protein 
expression through a sensitive ELISA developed in the lab. However, the 
concentration of LRG1 in the retinal lysates was below the detection limit of 
the ELISA (data not shown). A second aim of the studies with the hLRG1 KI 
mice was to confirm that these mice responded in the same way as WT 
mice to diabetes induction. Replacement of the mouse gene with the human 
cDNA, albeit at the correct locus in the mouse genome, could potentially 
lead to altered regulation of transcription and translation compared to the 
endogenous mouse gene. This could be mediated by differences in the 
affinity of transcription factors to promoter sequences within the coding 
region of this gene, due to slight differences in the sequence of human and 
mouse LRG1. In addition, since the cDNA sequence was inserted, it may 
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lack non-coding RNA enhancer sequences present in the intron (Li et al. 
2016), an example of which is found in the intronic sequence of IL-4 (Hural 
et al. 2000).  
 
Therefore it was important to ensure that these mice had a diabetic retinal 
phenotype similar to WT mice to validate this mouse model before further 
experiments were conducted. Analysis of endogenous IgG by 
immunofluorescence indeed confirmed that a similar retinal phenotype 
developed after diabetes induction as in WT mice. This finding indicates that 
this model is suitable for further study into the role of Lrg1 in the diabetic 
retina, and may be particularly useful for in vivo testing of a humanised 
function-blocking anti-LRG1 antibody developed in the lab. 
 
In summary, data in this thesis from the investigation of the diabetic retina 
highlights an important role for inflammation in mediating early diabetes-
induced pathophysiological changes as described by the increase in Nf-κb 
phosphorylation, altered microglial/macrophage activation and migration, 
and oxidative stress, which are in agreement with data from the 
streptozotocin mouse and other models of diabetic retinopathy. Whilst 
neither high glucose nor AGE-BSA treatment in the metatarsal assay 
completely recreated diabetes induced vascular dysfunction in the 
metatarsal assay, the pro-angiogenic and pro-inflammatory effect of AGE-
BSA treatment means that it has greater potential for investigating 
inflammation-induced vascular dysfunction. Further work to explore the 
mechanisms behind diabetes-induced retinal inflammation could therefore 
identify new therapeutic targets, which could be utilised in the clinic prior to 
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the onset of vascular dysfunction. More specifically, characterising the role 
of Lrg1 in diabetes-associated vascular changes may indicate a potential 
utility for LRG1 blockade in the early stages of diabetic retinopathy. 
 
This research in the diabetic mouse retina has identified three candidate 
factors with potential for use in the management of diabetic retinopathy. 
Whilst LRG1 cannot be considered as a new therapeutic target, the research 
in this thesis can be considered has acted as a ‘proof of concept’ that LRG1 
is involved in the pathogenesis of diabetic retinopathy and existing 
therapeutics which are currently being developed could be utilised to treat 
diabetic retinopathy. 
 
Two other factors were identified, Angptl2 and Angptl6 in the diabetic 
mouse retina. Unlike Lrg1, which has already been characterised and 
established as an appropriate therapeutic target, Angptl2 and Angptl6 have 
not been as well characterised. Further work must be done before either 
candidate can be considered to be an effective therapeutic target. In order 
to do this, one must demonstrate that Angptl2 and/or Angptl6 mediate an 
aspect(s) of the pathophysiology of diabetic retinopathy, which can be 
effectively targeted without having a deleterious off-target effect. Research 
into both factors could be performed to see if the absence of either has a 
protective effect on the diabetic retina without causing deleterious effects 
on the retina. Additionally administration of either factor to the retina in 
non-diabetic mice should be able to recreate some of the features of 
diabetic retinopathy in these mice, this would confirm that this factor 
contributes to specific features of diabetic retinopathy. Secondly, these 
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factors should also be confirmed to be increased in human patients with 
diabetic retinopathy, ethical approval would have to be sought to utilise 
human vitreous samples to test this hypothesis in humans. Having 
confirmed this, an effective mechanism of blocking or inhibiting the effect of 
either factor should be designed which acts specifically on either factor 
without any adverse effect. If the described studies above demonstrate a 
clear role for either Angptl2 or Angptl6 this would generate data sufficient 
for publication in a peer-reviewed journal with a strong translational aspect 
which could lead to the development of a novel therapeutic. 
 
In addition to the work to perform with the aim of identifying novel 
therapeutic targets described above, further studies with the metatarsal 
assay could be performed with the aim to identify mechanisms leading to 
diabetes-induced vascular regression. Whilst hyperglycaemia did not alter 
pericyte coverage in this model, the behaviour of other cell types such as 
smooth muscle cells and fibroblasts may instead be altered which could 
potentially lead to impaired tissue vascularisation. I believe that these other 
cell types may be reduced or otherwise negatively affected by 
hyperglycaemia, which would impair endothelial cell growth and survival.  
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Figure 31: A summary of the main findings of this thesis. 
  
Metatarsal	assay
High	glucose	inhibits	angiogenesis	in	the	metatarsal	assay
AGE-BSA	may	potentially	induce	angiogenesis	in	the	metatarsal	assay	by	activating	pro-inflammatory	signalling
Streptozotocin-induced	diabetesDiabetes-induced	inflammation	appears	to	be	the	most	important	syptom	of	pathology	in	the	retina
Angptl2,	Angptl6 and	Lrg1are	all	upregulated	in	the	diabetic	mouse	retinaThe	Lrg1	KO	mouse	has	a	less	severe	retinal	phenotype	compared	to	WT	diabetic	mice
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